<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Vet Sci</journal-id><journal-id journal-id-type="iso-abbrev">Vet Sci</journal-id><journal-id journal-id-type="publisher-id">vetsci</journal-id><journal-title-group><journal-title>Veterinary Sciences</journal-title></journal-title-group><issn pub-type="epub">2306-7381</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.3390/vetsci2040456</article-id><article-id pub-id-type="publisher-id">vetsci-02-00456</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Efficacy of Antiviral Drugs against Feline Immunodeficiency Virus</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hartmann</surname><given-names>Katrin</given-names></name><xref rid="c1-vetsci-02-00456" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Wooding</surname><given-names>Anita</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bergmann</surname><given-names>Mich&#x000e8;le</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Sparger</surname><given-names>Ellen (Liz)</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Sykes</surname><given-names>Jane</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vetsci-02-00456">Clinic of Small Animal Medicine, LMU Munich, Veterinaerstrasse 13, 80539 Munich, Germany; E-Mails: <email>anitaschwartz@hotmail.com</email> (A.W.); <email>n.bergmann@medizinische-kleintierklinik.de</email> (M.B.)</aff><author-notes><corresp id="c1-vetsci-02-00456"><label>*</label>Author to whom correspondence should be addressed; E-Mail: <email>hartmann@uni-muenchen.de</email>; Tel.: +49-89-2180-2650.</corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2015</year></pub-date><volume>2</volume><issue>4</issue><fpage>456</fpage><lpage>476</lpage><history><date date-type="received"><day>14</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>21</day><month>10</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 by the authors.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Feline immunodeficiency virus (FIV) is one of the most common infectious agents affecting cats worldwide .FIV and human immunodeficiency virus (HIV) share many properties: both are lifelong persistent lentiviruses that are similar genetically and morphologically and both viruses propagate in T-lymphocytes, macrophages, and neural cells. Experimentally infected cats have measurable immune suppression, which sometimes progresses to an acquired immunodeficiency syndrome. A transient initial state of infection is followed by a long latent stage with low virus replication and absence of clinical signs. In the terminal stage, both viruses can cause severe immunosuppression. Thus, FIV infection in cats has become an important natural model for studying HIV infection in humans, especially for evaluation of antiviral compounds. Of particular importance for chemotherapeutic studies is the close similarity between the reverse transcriptase (RT) of FIV and HIV, which results in high <italic>in vitro</italic> susceptibility of FIV to many RT-targeted antiviral compounds used in the treatment of HIV-infected patients. Thus, the aim of this article is to provide an up-to-date review of studies on antiviral treatment of FIV, focusing on commercially available compounds for human or animal use.</p></abstract><kwd-group><kwd>FIV</kwd><kwd>antiviral compounds</kwd><kwd>treatment</kwd><kwd>therapy</kwd></kwd-group></article-meta></front><body><sec id="sec1-vetsci-02-00456"><title>1. Introduction</title><p>FIV can induce immunosuppression, which predisposes cats to secondary infections, stomatitis, neuropathies, and tumors. FIV does not directly cause severe clinical disease in most infected cats. Thus, FIV-infected cats can live with a good quality of life for many years with preventive health measures, and overall survival time of infected cats is not necessarily shorter than in uninfected cats [<xref rid="B1-vetsci-02-00456" ref-type="bibr">1</xref>,<xref rid="B2-vetsci-02-00456" ref-type="bibr">2</xref>,<xref rid="B3-vetsci-02-00456" ref-type="bibr">3</xref>]. The most important strategy for managing FIV-infected cats is treatment of secondary infections. In cats with recurrent infections despite aggressive management, additional treatment with antiviral drugs (e.g., plerixafor and/or zidovudine) can be considered. Cats with no identifiable secondary diseases or with secondary disease that has been treated successfully might still suffer from problems likely associated with FIV, such as neurologic abnormalities or stomatitis; in these cases, antiviral treatment (e.g., with zidovudine) is also an option.</p><p>Antiviral compounds interfere with certain steps in the viral replication cycle. Based upon steps targeted, the drugs can be assigned to different drug classes [<xref rid="B4-vetsci-02-00456" ref-type="bibr">4</xref>,<xref rid="B5-vetsci-02-00456" ref-type="bibr">5</xref>]. This review covers the most common drugs used for treatment of FIV infection (<xref ref-type="table" rid="vetsci-02-00456-t001">Table A1</xref>): reverse transcriptase inhibitors (RTIs), which inhibit the retroviral enzyme reverse transcriptase (RTIs); drugs that inhibit other viral enzymes, such as DNA or RNA polymerases, thereby interfering with virus genome replication or with proteinases necessary for splitting precursor proteins during viral assembly (nucleotide synthesis inhibitors); drugs that target viral entry by binding to specific receptors that the virus uses for adsorption to the target cell, by acting as fusion inhibitors preventing conformational changes of the virus necessary for the fusion process, or by interfering with viral uncoating (receptor homologues/antagonists) [<xref rid="B4-vetsci-02-00456" ref-type="bibr">4</xref>,<xref rid="B6-vetsci-02-00456" ref-type="bibr">6</xref>]; drugs that inhibit integration by inhibiting the retroviral enzyme integrase (integrase inhibitors); drugs that inhibit viral replication by inhibiting the retroviral enzyme protease (protease inhibitors); and interferons.</p><sec><title>Reverse Transcriptase Inhibitors</title><p>The most commonly used antiretroviral drugs in human and veterinary medicine are RTIs. There are three categories of RTIs: nucleoside analogue RTIs (NARTIs, <xref ref-type="sec" rid="sec1-vetsci-02-00456">Section 1</xref>), nucleotide analogue RTIs, <xref ref-type="sec" rid="sec2-vetsci-02-00456">Section 2</xref>, and non-nucleoside RTIs (NNRTIs, <xref ref-type="sec" rid="sec3-vetsci-02-00456">Section 3</xref>) [<xref rid="B5-vetsci-02-00456" ref-type="bibr">5</xref>,<xref rid="B7-vetsci-02-00456" ref-type="bibr">7</xref>]. A nucleoside consists of a nitrogenous base covalently attached to a sugar (ribose in RNA, 2-deoxyribose in DNA), and a nucleotide consists of a nitrogenous base, a sugar, and a phosphate group. Nucleic acid (RNA and DNA) contains a chain of nucleotides covalently linked to form a sugar-phosphate backbone with protruding nitrogenous bases. Prior to linkage of a new nucleotide (or monophosphate) to the nucleic acid, three phosphate groups must be bound to the nucleoside (triphosphate), two of which are removed, releasing energy during elongation of the nucleic acid chain [<xref rid="B5-vetsci-02-00456" ref-type="bibr">5</xref>].</p></sec></sec><sec id="sec2-vetsci-02-00456"><title>2. Nucleoside Analogue Reverse Transcriptase Inhibitors</title><p>NARTIs are the most widely used antiviral compounds in both human and veterinary medicine. NARTIs are molecules that are similar to the &#x0201c;true&#x0201d; nucleosides and require intracellular phosphorylation for activation. Due to their structural similarities, they can bind to the active center of enzymes (e.g., RT, other polymerases) and block enzyme activity. Many of these analogues are also integrated into growing DNA or RNA strands, but because of small differences in the molecular structure, chain termination results or nonfunctional nucleic acids are produced [<xref rid="B5-vetsci-02-00456" ref-type="bibr">5</xref>,<xref rid="B8-vetsci-02-00456" ref-type="bibr">8</xref>,<xref rid="B9-vetsci-02-00456" ref-type="bibr">9</xref>]. NARTIs are accepted as false substrates by viral enzymes as well as by cellular enzymes, which is the main reason for their toxicity [<xref rid="B10-vetsci-02-00456" ref-type="bibr">10</xref>].</p><sec id="sec2dot1-vetsci-02-00456"><title>2.1. Zidovudine</title><p>Zidovudine (3&#x02032;-azido-2&#x02032;,3&#x02032;-dideoxythymidine, AZT) was first synthesized in the 1960s [<xref rid="B11-vetsci-02-00456" ref-type="bibr">11</xref>] as a potential anticancer drug. In 1985 it was shown to be effective against HIV [<xref rid="B12-vetsci-02-00456" ref-type="bibr">12</xref>] and became the first drug approved for treatment of HIV infection [<xref rid="B13-vetsci-02-00456" ref-type="bibr">13</xref>].</p><p>The anti-FIV activity of zidovudine has been assessed in numerous <italic>in vitro</italic> studies in different cell systems [<xref rid="B14-vetsci-02-00456" ref-type="bibr">14</xref>,<xref rid="B15-vetsci-02-00456" ref-type="bibr">15</xref>,<xref rid="B16-vetsci-02-00456" ref-type="bibr">16</xref>,<xref rid="B17-vetsci-02-00456" ref-type="bibr">17</xref>,<xref rid="B18-vetsci-02-00456" ref-type="bibr">18</xref>,<xref rid="B19-vetsci-02-00456" ref-type="bibr">19</xref>,<xref rid="B20-vetsci-02-00456" ref-type="bibr">20</xref>,<xref rid="B21-vetsci-02-00456" ref-type="bibr">21</xref>,<xref rid="B22-vetsci-02-00456" ref-type="bibr">22</xref>,<xref rid="B23-vetsci-02-00456" ref-type="bibr">23</xref>,<xref rid="B24-vetsci-02-00456" ref-type="bibr">24</xref>,<xref rid="B25-vetsci-02-00456" ref-type="bibr">25</xref>,<xref rid="B26-vetsci-02-00456" ref-type="bibr">26</xref>]. The first <italic>in vitro</italic> study was carried out in 1989, when North and coworkers showed that zidovudine inhibited FIV replication in Crandell-Rees feline kidney (CRFK) cells. The susceptibility of FIV to zidovudine was similar to that of HIV [<xref rid="B27-vetsci-02-00456" ref-type="bibr">27</xref>]. There is evidence that FIV can become resistant to nucleoside analogues, as is the case in HIV. Zidovudine-resistant FIV mutants can arise after only six months of use, and a single-point mutation in the FIV gene is responsible for resistance [<xref rid="B10-vetsci-02-00456" ref-type="bibr">10</xref>].</p><p><italic>In vivo</italic>, zidovudine can reduce plasma viral load, improve the immunologic and clinical status of FIV-infected cats, increase quality of life, and prolong life expectancy [<xref rid="B16-vetsci-02-00456" ref-type="bibr">16</xref>]. In placebo-controlled trials, zidovudine improved stomatitis and increased the CD4/CD8 ratio in naturally FIV-infected cats. In some cats with FIV-associated neurologic signs, marked improvement was reported within the first days of therapy [<xref rid="B28-vetsci-02-00456" ref-type="bibr">28</xref>,<xref rid="B29-vetsci-02-00456" ref-type="bibr">29</xref>].</p><p>Zidovudine not only inhibits RT, but also cellular polymerases, and this can lead to bone marrow suppression. Regular blood cell counts are necessary during zidovudine treatment because non-regenerative anemia is a common side effect [<xref rid="B28-vetsci-02-00456" ref-type="bibr">28</xref>]. Cats with bone marrow suppression should not be treated with zidovudine. Most FIV-infected cats treated with zidovudine for as long as two years tolerated the drug well. The hematocrit can decline within three weeks of initiating treatment to approximately 50% of baseline but increases afterwards in most cases, even without discontinuation of treatment. If the hematocrit drops below 20%, discontinuation of treatment is recommended, and anemia usually resolves within a few days. Other side effects in cats, including vomiting or anorexia, are rare [<xref rid="B28-vetsci-02-00456" ref-type="bibr">28</xref>].</p></sec><sec id="sec2dot2-vetsci-02-00456"><title>2.2. Stavudine</title><p>Stavudine (2&#x02032;,3&#x02032;-didehydro-2&#x02032;,3&#x02032;-dideoxythymidine, d4T) is another drug effective against HIV. It was approved for treatment of HIV infection in 1994, but in recent years has been replaced in most multi-drug treatment protocols by compounds with fewer side effects [<xref rid="B30-vetsci-02-00456" ref-type="bibr">30</xref>,<xref rid="B31-vetsci-02-00456" ref-type="bibr">31</xref>,<xref rid="B32-vetsci-02-00456" ref-type="bibr">32</xref>,<xref rid="B33-vetsci-02-00456" ref-type="bibr">33</xref>,<xref rid="B34-vetsci-02-00456" ref-type="bibr">34</xref>].</p><p>Stavudine is active against FIV <italic>in vitro</italic> [<xref rid="B18-vetsci-02-00456" ref-type="bibr">18</xref>,<xref rid="B19-vetsci-02-00456" ref-type="bibr">19</xref>,<xref rid="B20-vetsci-02-00456" ref-type="bibr">20</xref>,<xref rid="B23-vetsci-02-00456" ref-type="bibr">23</xref>,<xref rid="B26-vetsci-02-00456" ref-type="bibr">26</xref>,<xref rid="B35-vetsci-02-00456" ref-type="bibr">35</xref>,<xref rid="B36-vetsci-02-00456" ref-type="bibr">36</xref>]. Mutants of FIV that are resistant to stavudine and cross-resistant to several other antivirals, including zidovudine, have been detected. Resistance is caused by a single-point mutation in the RT-encoding region of the <italic>pol</italic> gene [<xref rid="B26-vetsci-02-00456" ref-type="bibr">26</xref>]. No <italic>in vivo</italic> data in FIV-infected cats have been published.</p></sec><sec id="sec2dot3-vetsci-02-00456"><title>2.3. Didanosine</title><p>Didanosine (2&#x02032;,3&#x02032;-dideoxyinosine, ddl) was shown to be active against HIV in 1986 [<xref rid="B37-vetsci-02-00456" ref-type="bibr">37</xref>]. In the United States, it was the second drug to be approved for treatment of HIV and has been on the market since 1991 [<xref rid="B5-vetsci-02-00456" ref-type="bibr">5</xref>]. </p><p>Didanosine is active against FIV <italic>in vitro</italic> [<xref rid="B14-vetsci-02-00456" ref-type="bibr">14</xref>,<xref rid="B18-vetsci-02-00456" ref-type="bibr">18</xref>,<xref rid="B20-vetsci-02-00456" ref-type="bibr">20</xref>,<xref rid="B21-vetsci-02-00456" ref-type="bibr">21</xref>,<xref rid="B22-vetsci-02-00456" ref-type="bibr">22</xref>,<xref rid="B23-vetsci-02-00456" ref-type="bibr">23</xref>,<xref rid="B24-vetsci-02-00456" ref-type="bibr">24</xref>,<xref rid="B26-vetsci-02-00456" ref-type="bibr">26</xref>,<xref rid="B38-vetsci-02-00456" ref-type="bibr">38</xref>]. In one experimental <italic>in vivo</italic> study, FIV replication was significantly suppressed in animals treated with didanosine, but treatment contributed to the development of antiretroviral toxic neuropathy [<xref rid="B39-vetsci-02-00456" ref-type="bibr">39</xref>].</p></sec><sec id="sec2dot4-vetsci-02-00456"><title>2.4. Lamivudine</title><p>Lamivudine (2R,cis-4-amino-l-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, 3TC) is also an anti-HIV drug, approved in 1995 [<xref rid="B40-vetsci-02-00456" ref-type="bibr">40</xref>]. </p><p>Lamivudine is active against FIV <italic>in vitro</italic> [<xref rid="B3-vetsci-02-00456" ref-type="bibr">3</xref>,<xref rid="B20-vetsci-02-00456" ref-type="bibr">20</xref>,<xref rid="B21-vetsci-02-00456" ref-type="bibr">21</xref>,<xref rid="B23-vetsci-02-00456" ref-type="bibr">23</xref>,<xref rid="B38-vetsci-02-00456" ref-type="bibr">38</xref>,<xref rid="B41-vetsci-02-00456" ref-type="bibr">41</xref>]. A combination of zidovudine and lamivudine had synergistic anti-FIV activities in cell cultures [<xref rid="B41-vetsci-02-00456" ref-type="bibr">41</xref>]. FIV mutants resistant to lamivudine and containing a point mutation in the RT gene were selected <italic>in vitro</italic> and showed cross resistance to zidovudine [<xref rid="B23-vetsci-02-00456" ref-type="bibr">23</xref>]. </p><p>In one <italic>in vivo</italic> study, experimentally FIV-infected cats were treated with a high-dose zidovudine/lamivudine combination, which protected some cats from infection when treatment was started before virus inoculation. However, zidovudine/lamivudine treatment showed no anti-FIV activity in chronically infected cats. Severe side effects, including fever, anorexia, and marked hematologic changes, were observed in some of the cats with this high-dose dual-drug treatment [<xref rid="B41-vetsci-02-00456" ref-type="bibr">41</xref>]. Thus, high-dose lamivudine treatment alone, or in combination with zidovudine, is not recommended in naturally FIV-infected cats.</p></sec><sec id="sec2dot5-vetsci-02-00456"><title>2.5. Emtricitabine</title><p>Emtricitabine (2',3'-deoxy-5-fluoro-3'-thiacytidine, FTC) is structurally similar to lamivudine and was licensed by the FDA in 2003 [<xref rid="B40-vetsci-02-00456" ref-type="bibr">40</xref>]. <italic>In vitro</italic>, antiviral efficacy has been demonstrated against FIV [<xref rid="B17-vetsci-02-00456" ref-type="bibr">17</xref>,<xref rid="B20-vetsci-02-00456" ref-type="bibr">20</xref>,<xref rid="B21-vetsci-02-00456" ref-type="bibr">21</xref>,<xref rid="B22-vetsci-02-00456" ref-type="bibr">22</xref>], but to date there have been no <italic>in vivo</italic> studies in FIV-infected cats.</p></sec><sec id="sec2dot6-vetsci-02-00456"><title>2.6. Abacavir</title><p>Abacavir ((1<italic>S</italic>,4<italic>R</italic>)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, ABC) was shown to be active against HIV in 1986 and belongs to the FDA-approved anti-HIV compounds [<xref rid="B40-vetsci-02-00456" ref-type="bibr">40</xref>]. Abacavir is active against FIV <italic>in vitro,</italic> but had higher levels of cytotoxicity than other compounds, such as didanosine and amdoxovir [<xref rid="B16-vetsci-02-00456" ref-type="bibr">16</xref>,<xref rid="B20-vetsci-02-00456" ref-type="bibr">20</xref>]. There are no <italic>in vivo</italic> studies of this drug in FIV-infected cats.</p></sec></sec><sec id="sec3-vetsci-02-00456"><title>3. Nucleotide Analogue Reverse Transcriptase Inhibitors</title><p>Similar to NARTIs, NtARTIs also interact with the catalytic site of RT and are incorporated into the elongating proviral DNA strand, causing chain termination [<xref rid="B5-vetsci-02-00456" ref-type="bibr">5</xref>,<xref rid="B42-vetsci-02-00456" ref-type="bibr">42</xref>]. They compete with natural nucleotides and therefore function as competitive substrate inhibitors. However, in contrast to NARTIs, NtARTIs already contain one phosphate group and thus need only two intracellular phosphorylation steps for conversion to their active forms because the first and often rate-limiting phosphorylation step is unnecessary [<xref rid="B5-vetsci-02-00456" ref-type="bibr">5</xref>,<xref rid="B42-vetsci-02-00456" ref-type="bibr">42</xref>,<xref rid="B43-vetsci-02-00456" ref-type="bibr">43</xref>].</p><sec id="sec3dot1-vetsci-02-00456"><title>3.1. Adefovir</title><p>Adefovir (2-(6-amino-9H-purin-9-yl)-ethoxy-methyl-phosphonic acid, PMEA) is active against herpesviruses, hepadnaviruses (hepatitis B), and retroviruses [<xref rid="B44-vetsci-02-00456" ref-type="bibr">44</xref>]. Adefovir is not licensed as an HIV drug, but is currently available as an oral formulation (bis-POM PMEA) approved for the treatment of chronic hepatitis B. Adefovir belongs to the acyclic nucleoside phosphonates, in which the alkyl side chain of purines and pyrimidines is linked to a modified phosphate moiety and a C-P phosphonate linkage replaces the normal O5&#x02032;-P phosphate linkage [<xref rid="B43-vetsci-02-00456" ref-type="bibr">43</xref>,<xref rid="B45-vetsci-02-00456" ref-type="bibr">45</xref>]. This phosphonate bond is not hydrolysable, which makes it more difficult to cleave off these compounds once they have been incorporated at the 3&#x02032;-terminal end of the elongating proviral DNA strand [<xref rid="B5-vetsci-02-00456" ref-type="bibr">5</xref>]. Adefovir inhibits FIV replication <italic>in vitro</italic> [<xref rid="B46-vetsci-02-00456" ref-type="bibr">46</xref>]. </p><p>Several studies have investigated the efficacy of adefovir in either experimentally and naturally FIV-infected cats [<xref rid="B47-vetsci-02-00456" ref-type="bibr">47</xref>,<xref rid="B48-vetsci-02-00456" ref-type="bibr">48</xref>,<xref rid="B49-vetsci-02-00456" ref-type="bibr">49</xref>,<xref rid="B50-vetsci-02-00456" ref-type="bibr">50</xref>,<xref rid="B51-vetsci-02-00456" ref-type="bibr">51</xref>,<xref rid="B52-vetsci-02-00456" ref-type="bibr">52</xref>,<xref rid="B53-vetsci-02-00456" ref-type="bibr">53</xref>]. A few of those studies showed some efficacy, but also reported severe side effects, mainly non-regenerative anemia. In a recent study, adefovir was administered to FIV-infected cats in a six-week placebo-controlled, double-blinded clinical trial; ten cats received adefovir (10 mg/kg SC twice weekly) and ten cats received placebo. There was no decrease in proviral or viral loads in treated cats, and treated cats developed a progressive, sometimes life-threatening anemia, which is a common adverse effect of NtARTIs [<xref rid="B53-vetsci-02-00456" ref-type="bibr">53</xref>]. This shows that results obtained in experimental studies cannot always be applied to a field situation and emphasizes the importance of controlled clinical field trials. Based on the lack of efficacy in the recent placebo-controlled field trial and the side effects, adefovir cannot be recommended for treatment of FIV-infected cats.</p></sec><sec id="sec3dot2-vetsci-02-00456"><title>3.2. Tenofovir</title><p>Currently, the only approved NtARTi for the treatment of HIV infection is tenofovir disoproxil fumarate (TDF), the prodrug of tenofovir ((R)-9-(2-phosphonylmethoxypropyl)adenine, (R)-PMPA), which is also a member of the acyclic nucleoside phosphonates [<xref rid="B43-vetsci-02-00456" ref-type="bibr">43</xref>,<xref rid="B45-vetsci-02-00456" ref-type="bibr">45</xref>]. The antiviral spectrum of tenofovir (2R-1-(6-amino-9H-purin-9-yl)-propan-2-yl-oxy-methyl-phosphonic acid, PMPA) is narrower than that of adefovir; it does not encompass herpesviruses, but is confined to hepadna- and retroviruses [<xref rid="B44-vetsci-02-00456" ref-type="bibr">44</xref>]. Tenofovir disoproxil fumarate has become one of the most commonly used drugs in HIV therapy since its licensing in 2001 [<xref rid="B5-vetsci-02-00456" ref-type="bibr">5</xref>,<xref rid="B9-vetsci-02-00456" ref-type="bibr">9</xref>].</p><p>Tenofovir is effective against FIV <italic>in vitro</italic> [<xref rid="B25-vetsci-02-00456" ref-type="bibr">25</xref>,<xref rid="B45-vetsci-02-00456" ref-type="bibr">45</xref>], and there is some evidence that tenovovir might have greater anti-FIV efficacy with less cytotoxicity than other antiretroviral compounds, including adefovir [<xref rid="B45-vetsci-02-00456" ref-type="bibr">45</xref>,<xref rid="B54-vetsci-02-00456" ref-type="bibr">54</xref>]. However, <italic>in vivo</italic> studies are lacking and should be a focus of future research.</p></sec></sec><sec id="sec4-vetsci-02-00456"><title>4. Non-Nucleoside Reverse Transcriptase Inhibitors</title><p>Most of the NNRTIs are highly specific for HIV-1 and are not active against other retroviruses, including HIV-2 and FIV [<xref rid="B7-vetsci-02-00456" ref-type="bibr">7</xref>,<xref rid="B42-vetsci-02-00456" ref-type="bibr">42</xref>]. Unlike NARTIs and NtARTIs, which bind to the catalytic site of RT, non-nucleoside RT inhibitors interact with an allosteric site of the enzyme [<xref rid="B5-vetsci-02-00456" ref-type="bibr">5</xref>] and are not incorporated into the proviral DNA strand [<xref rid="B42-vetsci-02-00456" ref-type="bibr">42</xref>]. They are classified as non-competitive inhibitors of RT and do not require intracellular activation for inhibition of the enzyme [<xref rid="B8-vetsci-02-00456" ref-type="bibr">8</xref>,<xref rid="B42-vetsci-02-00456" ref-type="bibr">42</xref>]. NNRTIs are a group of structurally diverse compounds that all bind a single site of the RT [<xref rid="B55-vetsci-02-00456" ref-type="bibr">55</xref>]. The interaction with the allosteric site which is located in close proximity to the catalytic site, leads to a number of conformational changes of the RT [<xref rid="B55-vetsci-02-00456" ref-type="bibr">55</xref>,<xref rid="B56-vetsci-02-00456" ref-type="bibr">56</xref>]. Among other effects, these changes cause a reduction in the interaction between the DNA primer and the polymerase domain of the enzyme and thus, inhibit virus replication [<xref rid="B55-vetsci-02-00456" ref-type="bibr">55</xref>,<xref rid="B56-vetsci-02-00456" ref-type="bibr">56</xref>].</p><p>Three of the FDA-approved NNRTIs (nevirapine, delavirdine, efavirenz) have been shown not to be effective against FIV <italic>in vitro</italic> [<xref rid="B40-vetsci-02-00456" ref-type="bibr">40</xref>,<xref rid="B57-vetsci-02-00456" ref-type="bibr">57</xref>]. <italic>In vivo</italic> studies have not been performed, presumably because of the lack of <italic>in vitro</italic> efficacy [<xref rid="B7-vetsci-02-00456" ref-type="bibr">7</xref>,<xref rid="B57-vetsci-02-00456" ref-type="bibr">57</xref>]. Only one old NNRTI, suramin, with a broad antiviral spectrum has been used in veterinary medicine. A major breakthrough in the treatment of FIV would be the discovery of more NNRTIs with activity against FIV RT.</p><sec><title>Suramin</title><p>Suramin (1-(3-benzamido-4-methylbenzamido)-naphthalene 4,6,8-trisulfonic acid sym-3&#x02032;-urea sodium salt), a sulfated naphthylamine and trypan red derivative, is one of the oldest known antimicrobial agents. It has been used as an antitrypanosomal agent and for the treatment of some tumors, such as prostate cancer [<xref rid="B58-vetsci-02-00456" ref-type="bibr">58</xref>]. It also has an inhibitory effect on the RT activity of retroviruses and has also been used in humans with HIV infection [<xref rid="B59-vetsci-02-00456" ref-type="bibr">59</xref>]. Suramin inhibits RT by interacting with the template-primer binding site of the enzyme. Thus, it competitively binds to the primer binding site (without being a nucleoside analogue) and inhibits the template-primer binding that is necessary for DNA elongation. Suramin can therefore be classified as an NNRTI [<xref rid="B60-vetsci-02-00456" ref-type="bibr">60</xref>].</p><p>Suramin is effective against feline leukemia virus (FeLV) <italic>in vivo</italic> [<xref rid="B61-vetsci-02-00456" ref-type="bibr">61</xref>,<xref rid="B62-vetsci-02-00456" ref-type="bibr">62</xref>], and thus, could potentially be active against FIV, although this has not been investigated.</p><p>Suramin is associated with a significant number of severe side effects in humans, such as nausea and anaphylactic shock as immediate reactions during administration and peripheral neuritis leading to palmar-plantar hyperesthesia, photophobia, skin reactions, agranulocytosis, hemolytic anemia, and destruction of the adrenal cortex as later side effects [<xref rid="B58-vetsci-02-00456" ref-type="bibr">58</xref>,<xref rid="B59-vetsci-02-00456" ref-type="bibr">59</xref>,<xref rid="B63-vetsci-02-00456" ref-type="bibr">63</xref>,<xref rid="B64-vetsci-02-00456" ref-type="bibr">64</xref>,<xref rid="B65-vetsci-02-00456" ref-type="bibr">65</xref>]. In cats with FeLV infection, the major adverse effects of suramin were transient vomiting and anorexia [<xref rid="B61-vetsci-02-00456" ref-type="bibr">61</xref>].</p></sec></sec><sec id="sec5-vetsci-02-00456"><title>5. Nucleotide Synthesis Inhibitors</title><p>Nucleotide synthesis inhibitors prevent synthesis of nucleotides through various mechanisms. They have a broad spectrum of activity but are associated with marked toxicity mainly because they are non-selective and therefore also interfere with normal cellular nucleotide synthesis. Some, for instance foscarnet, interfere with the exchange of pyrophosphate from deoxynucleoside triphosphate during viral replication by binding to RT or DNA polymerase, thereby preventing nucleotide synthesis [<xref rid="B66-vetsci-02-00456" ref-type="bibr">66</xref>]. Others, such as ribavirin, inhibit inosine monophosphate dehydrogenase after intracellular phosphorylation, which in turn leads to inhibition of guanosine monophosphate.</p><sec id="sec5dot1-vetsci-02-00456"><title>5.1. Foscarnet</title><p>Foscarnet (phosphonoformic acid, PFA) has broad-spectrum antiviral activity against DNA and RNA viruses, including retroviruses. It is FDA-approved for the treatment of HIV-associated cytomegalo and herpes simplex virus infections in humans [<xref rid="B67-vetsci-02-00456" ref-type="bibr">67</xref>]. Foscarnet is usually administered intravenously by continuous intravenous infusion because of its short half-life, which has also been demonstrated in cats [<xref rid="B68-vetsci-02-00456" ref-type="bibr">68</xref>]. Oral administration of the drug is possible but can result in irritation of mucous membranes and oral bleeding. Foscarnet has many side effects, including nephrotoxicity and myelosuppression, in both humans and cats. It also is toxic to epithelial cells and mucous membranes, resulting in gastrointestinal side effects and genital epithelium ulceration. In addition, it chelates various cations, which can lead to hypocalcemia, hypomagnesemia, and hypokalemia [<xref rid="B69-vetsci-02-00456" ref-type="bibr">69</xref>,<xref rid="B70-vetsci-02-00456" ref-type="bibr">70</xref>].</p><p><italic>In vitro</italic>, foscarnet has been shown to be active against FIV, but foscarnet-resistant FIV strains can develop [<xref rid="B14-vetsci-02-00456" ref-type="bibr">14</xref>]. No <italic>in vivo</italic> studies in FIV-infected cats have been carried out, likely because of the severe side effects and necessity for continuous intravenous administration of the drug. </p></sec><sec id="sec5dot2-vetsci-02-00456"><title>5.2. Ribavirin</title><p>Ribavirin (1-&#x003b2;-<sc>d</sc>-ribofuranosyl-1 H-1,2,4-triazole-3-carboxamide, RTCA) has marked <italic>in vitro</italic> antiviral activity against a variety of DNA and RNA viruses [<xref rid="B71-vetsci-02-00456" ref-type="bibr">71</xref>]. Systemic administration of ribavirin is limited in cats because of side effects [<xref rid="B72-vetsci-02-00456" ref-type="bibr">72</xref>]. Sequestration of ribavirin within erythrocytes results in hemolysis, even when low doses of the drug are used [<xref rid="B73-vetsci-02-00456" ref-type="bibr">73</xref>,<xref rid="B74-vetsci-02-00456" ref-type="bibr">74</xref>]. In addition, there is a dose-related toxic effect on bone marrow, primarily on megakaryocytes, resulting in thrombocytopenia and hemorrhage. With prolonged ribavirin treatment or at higher doses, the production of erythrocytes and neutrophils also is suppressed. Ribavirin also can induce hepatic toxicity. An attempt to decrease the toxicity of ribavirin by incorporating it into lecithin-containing liposomes and administering it at lower doses was not successful [<xref rid="B75-vetsci-02-00456" ref-type="bibr">75</xref>]. </p><p>Ribavirin is active against many viruses <italic>in vitro</italic>, including FIV [<xref rid="B23-vetsci-02-00456" ref-type="bibr">23</xref>,<xref rid="B76-vetsci-02-00456" ref-type="bibr">76</xref>]. Therapeutic concentrations are difficult to achieve <italic>in vivo</italic> because of toxicity [<xref rid="B74-vetsci-02-00456" ref-type="bibr">74</xref>]. To date, the efficacy of ribavirin has not been investigated in FIV-infected cats.</p></sec></sec><sec id="sec6-vetsci-02-00456"><title>6. Receptor Homologues/Antagonists</title><p>Receptor homologues/antagonists bind to the virus or to the cellular receptor, leading to inhibition of viral cell-surface binding. Most of the receptor homologues/antagonists are highly selective for HIV and not useful in veterinary medicine. An exception is the class of antiviral compounds called bicyclams, which have been used in cats with FIV infection. Bicyclams act as potent and selective CXC chemokine receptor 4 (CXCR4) antagonists [<xref rid="B77-vetsci-02-00456" ref-type="bibr">77</xref>,<xref rid="B78-vetsci-02-00456" ref-type="bibr">78</xref>]. Chemokine receptors belong to the group of seven transmembrane-proteins that enable signal transmission through rapid influx of calcium into the cell. They are essential co-receptors for HIV as well as for FIV during infection of CD4+ lymphocytes [<xref rid="B79-vetsci-02-00456" ref-type="bibr">79</xref>,<xref rid="B80-vetsci-02-00456" ref-type="bibr">80</xref>]. By binding to CXCR4, bicyclams prevent interaction of CXCR4 with other ligands, thereby inhibiting the entry of HIV or FIV into the cell [<xref rid="B81-vetsci-02-00456" ref-type="bibr">81</xref>,<xref rid="B82-vetsci-02-00456" ref-type="bibr">82</xref>,<xref rid="B83-vetsci-02-00456" ref-type="bibr">83</xref>].</p><sec><title>Plerixafor</title><p>Plerixafor (1,1&#x02032;-(1,4-phenylenbismethylene)-bis(1,4,8,11-tetraazacyclotetradecane)-octachlo-ride dehydrate, AMD3100) is the bicyclam prototype compound. It is not marketed as an anti-HIV drug, but is used in humans for stem cell mobilization [<xref rid="B84-vetsci-02-00456" ref-type="bibr">84</xref>]. </p><p>Plerixafor is active against FIV <italic>in vitro</italic> [<xref rid="B82-vetsci-02-00456" ref-type="bibr">82</xref>]. In a placebo-controlled double-blinded clinical trial, treatment of naturally FIV-infected cats with plerixafor resulted in a significant decrease in proviral load in treated cats when compared to the placebo group. There was a concomitant decrease in serum magnesium levels, which did not produce any clinical consequences. Development of resistance of FIV isolates to plerixafor did not occur during treatment [<xref rid="B53-vetsci-02-00456" ref-type="bibr">53</xref>]. In cats, plerixafor is administered at a dosage of 0.5 mg/kg every 12 h. Monitoring of magnesium and calcium levels should be performed at regular intervals during treatment [<xref rid="B53-vetsci-02-00456" ref-type="bibr">53</xref>]. Further studies investigating the potential of this promising drug are needed.</p></sec></sec><sec id="sec7-vetsci-02-00456"><title>7. Protease Inhibitors</title><p>Protease inhibitors (PI) specifically bind to the active site of the protease and therefore prevent viral replication. Several PIs have been used for successful treatment of HIV. Nevertheless, side effects and development of viral resistance were found during treatment, and therefore additional compounds that bind to sites other than the active site of the protease have been developed [<xref rid="B85-vetsci-02-00456" ref-type="bibr">85</xref>,<xref rid="B86-vetsci-02-00456" ref-type="bibr">86</xref>,<xref rid="B87-vetsci-02-00456" ref-type="bibr">87</xref>].</p><sec id="sec7dot1-vetsci-02-00456"><title>7.1. Tipranavir</title><p>Tipranavir (<italic>N</italic>-[3-[(1<italic>R</italic>)-1-[(2<italic>R</italic>)-6-hydroxy-4-oxo-2-(2-phenylethyl)-2-propyl-3<italic>H</italic>-pyran-5-yl]propy l]phenyl]-5-(trifluoromethyl)pyridin-2-sulfonamid) was approved in 2005, and is used as an anti-HIV compound. The drug was shown to be active against FIV <italic>in vitro</italic>.Tipranavir completely prevented FIV replication [<xref rid="B85-vetsci-02-00456" ref-type="bibr">85</xref>,<xref rid="B86-vetsci-02-00456" ref-type="bibr">86</xref>]. No studies in FIV-infected cats exist so far, and further studies are needed to investigate the potential of tipranavir in naturally infected cats.</p></sec><sec id="sec7dot2-vetsci-02-00456"><title>7.2. Lopinavir</title><p>Lopinavir (2<italic>S</italic>)-<italic>N</italic>-[(2<italic>S</italic>,4<italic>S</italic>,5<italic>S</italic>)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhex-an-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide) is an anti-HIV compound, approved in 2001. The drug was shown to be active against FIV <italic>in vitro</italic> but did not prevent FIV replication completely [<xref rid="B85-vetsci-02-00456" ref-type="bibr">85</xref>]. There are no <italic>in vivo</italic> studies in FIV-infected cats.</p></sec><sec id="sec7dot3-vetsci-02-00456"><title>7.3. Atazanavir</title><p>Atazanavir (methyl N-[(2R)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2R)-2-(methoxycarbonylamino)-3,3-di-methylbutanoyl]amino]-4-(2,3,4,5,6-pentadeuteriophenyl)butyl]-2-[(4-pyridin-2-ylphenyl)methyl]hy-drazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate) was licensed by the FDA in 2003 and is also used as an anti-HIV compound. Similar to lopinavir, some efficacy of atazanavir was shown against FIV <italic>in vitro</italic>, but there are no <italic>in vivo</italic> studies published so far [<xref rid="B85-vetsci-02-00456" ref-type="bibr">85</xref>].</p></sec></sec><sec id="sec8-vetsci-02-00456"><title>8. Integrase Inhibitors</title><p>The enzyme integrase catalyzes strand transfer (3&#x02032;-end joining), which inserts both viral DNA ends into a host cell chromosome during proviral DNA integration [<xref rid="B5-vetsci-02-00456" ref-type="bibr">5</xref>,<xref rid="B88-vetsci-02-00456" ref-type="bibr">88</xref>]. Once integrated, the provirus persists in the host cell genome and functions as a template for replication of the viral genome, leading to the formation of new viruses [<xref rid="B89-vetsci-02-00456" ref-type="bibr">89</xref>]. The high degree of conservation of integrase-active sites across many retroviruses suggests that FIV might also be sensitive to integrase inhibitors [<xref rid="B90-vetsci-02-00456" ref-type="bibr">90</xref>]. Integrase inhibitors act through inhibition of integration of the proviral DNA that is produced by reverse transcription of the viral RNA genome [<xref rid="B91-vetsci-02-00456" ref-type="bibr">91</xref>].</p><sec><title>Raltegravir</title><p>Raltegravir is used as an anti-HIV compound. The drug was shown to be active against FIV <italic>in vitro</italic> [<xref rid="B92-vetsci-02-00456" ref-type="bibr">92</xref>], but FIV was less susceptible to raltegravir than HIV [<xref rid="B92-vetsci-02-00456" ref-type="bibr">92</xref>]. </p><p>No studies in FIV-infected cats exist so far. Although there are no <italic>in vivo</italic> studies on the efficacy of raltegravir in FIV-infected cats, the drug recently was shown to be effective against FeLV and was safe in cats [<xref rid="B93-vetsci-02-00456" ref-type="bibr">93</xref>].</p></sec></sec><sec id="sec9-vetsci-02-00456"><title>9. Interferons</title><p>Interferons (IFNs) are polypeptide molecules with various biological functions [<xref rid="B94-vetsci-02-00456" ref-type="bibr">94</xref>]. They play an important role in mediating antiviral and antigrowth responses and in immune response modulation [<xref rid="B95-vetsci-02-00456" ref-type="bibr">95</xref>]. They can be divided into type I and type II IFNs, both of which have antiviral properties. Type I IFNs, including IFN-&#x003b1;, IFN-&#x003b2;, and IFN-&#x003c9;, are produced by virus-infected cells [<xref rid="B94-vetsci-02-00456" ref-type="bibr">94</xref>,<xref rid="B96-vetsci-02-00456" ref-type="bibr">96</xref>], whereas type II IFN, consisting of only IFN-&#x003b3;, is produced by activated T lymphocytes and natural killer cells in response to recognition of virus-infected cells [<xref rid="B97-vetsci-02-00456" ref-type="bibr">97</xref>]. IFNs act in an autocrine or paracrine fashion [<xref rid="B98-vetsci-02-00456" ref-type="bibr">98</xref>] inducing an anti-viral state in non-infected cells. IFNs bind to specific cell surface receptors and result in the transcription of IFN-stimulated genes. The products of these genes are proteins with potent anti-viral properties that interfere with various stages of viral replication [<xref rid="B98-vetsci-02-00456" ref-type="bibr">98</xref>]. Several studies suggest that retroviral protein synthesis is not affected by IFNs and therefore conclude that the antiviral activity of IFNs is mainly related to interference with later stages of the viral replication cycle such as virion assembly and release [<xref rid="B94-vetsci-02-00456" ref-type="bibr">94</xref>,<xref rid="B99-vetsci-02-00456" ref-type="bibr">99</xref>]. Interferons also trigger virus-infected cells to undergo apoptosis by activating gene expression for apoptosis [<xref rid="B97-vetsci-02-00456" ref-type="bibr">97</xref>,<xref rid="B99-vetsci-02-00456" ref-type="bibr">99</xref>], which prevents the spread of virus from infected cells and aids in the clearance of virus infection [<xref rid="B97-vetsci-02-00456" ref-type="bibr">97</xref>]. Human IFNs have been manufactured by recombinant DNA technology and are available commercially. Recombinant feline IFN-&#x003c9; is on the market in Japan, Australia, and many European countries and is licensed for use in cats and dogs.</p><sec id="sec9dot1-vetsci-02-00456"><title>9.1. Human Interferon-&#x003b1;</title><p>Recombinant human interferon-&#x003b1; (rHuIFN-&#x003b1;) has antiviral and immune-modulatory activity. IFN-&#x003b1; is active against many DNA and RNA viruses [<xref rid="B98-vetsci-02-00456" ref-type="bibr">98</xref>]. There are two common treatment regimens for use of rHuIFN-&#x003b1; in cats: SC injection (10<sup>4</sup> to 10<sup>6</sup> U/kg every 24 h) or oral application (1 to 50 U/kg every 24 h). </p><p>Human IFN-&#x003b1; becomes ineffective after three to seven weeks of parenteral use in cats because of the production of neutralizing antibodies [<xref rid="B100-vetsci-02-00456" ref-type="bibr">100</xref>]. Anti-IFN-&#x003b1; antibody production does not occur with oral administration of IFN-&#x003b1; and therefore this route allows for a longer period of treatment. IFN-&#x003b1; is inactivated by gastric acid and destroyed by trypsin and other proteolytic enzymes in the duodenum [<xref rid="B101-vetsci-02-00456" ref-type="bibr">101</xref>], which means that direct antiviral effects are unlikely after oral application. However, oral IFN-&#x003b1; appears to have immuno-modulatory activity, because it can stimulate local lymphoid tissue. The release of cytokines by lymphatic cells in the oropharyngeal area triggers a cascade of immunologic responses with systemic effects [<xref rid="B102-vetsci-02-00456" ref-type="bibr">102</xref>,<xref rid="B103-vetsci-02-00456" ref-type="bibr">103</xref>,<xref rid="B104-vetsci-02-00456" ref-type="bibr">104</xref>].</p><p>RHuIFN-&#x003b1; has been shown to be active against FIV <italic>in vitro</italic> [<xref rid="B105-vetsci-02-00456" ref-type="bibr">105</xref>]. Although frequently used in the field for treating FIV-infected cats, controlled studies evaluating the effect of parenteral administration of rHuIFN-&#x003b1; in FIV-infected cats have not been conducted. </p><p>Use of oral rHuIFN-&#x003b1; in 24 ill, naturally FIV-infected cats (50 U/kg applied to the oral mucosa daily for seven days on alternating weeks for six months, followed by a two-month break, and then repetition of the six-month treatment) resulted in improvement of clinical signs (e.g., fever, lymphadenopathy, opportunistic infections) in a placebo-controlled, double-blinded study [<xref rid="B106-vetsci-02-00456" ref-type="bibr">106</xref>]. However, proviral and viral loads were not monitored during thiat study and therefore it is impossible to conclude whether treatment with rHuIFN- &#x003b1; had indeed an effect on FIV, or rather on secondary infections.</p></sec><sec id="sec9dot2-vetsci-02-00456"><title>9.2. Feline Interferon-&#x003c9;</title><p>Recombinant feline interferon-&#x003c9; (rFeIFN-&#x003c9;), the corresponding feline interferon, is licensed for use in veterinary medicine in Japan, Australia, and some European countries. It can be used in cats for long periods without antibody development, and no major severe side effects have been reported [<xref rid="B107-vetsci-02-00456" ref-type="bibr">107</xref>].</p><p>IFN-&#x003c9; inhibits FIV replication <italic>in vitro</italic> [<xref rid="B105-vetsci-02-00456" ref-type="bibr">105</xref>]. One placebo-controlled, multicenter study that investigated the effect of parenteral rFeIFN-&#x003c9; against FIV infection in 62 naturally FIV-infected cats (treated with 10<sup>6</sup> U/kg SC q 24 h on five consecutive days) did not find a difference in the survival rate in treated cats. However, some improvement in clinical scores, including eight categories of clinical signs (rectal temperature, behavior, appetite, thirst, dehydration, mucous membrane appearance, stomatitis, and death) as well as improvement in laboratory abnormalities (leukopenia, leukocytosis, and anemia) occured [<xref rid="B107-vetsci-02-00456" ref-type="bibr">107</xref>]. In another study, which evaluated naturally FIV-infected cats housed in a shelter, some clinical improvement was observed after parenteral rFeIFN-&#x003c9; (10<sup>6</sup> U/kg SC q 24 h on FIVe consecutive days for three cycles), but this study lacked a placebo control. In that same study, hematologic values remained within reference intervals, and there were no biochemical abnormalities associated with rFeIFN-&#x003c9; treatment [<xref rid="B96-vetsci-02-00456" ref-type="bibr">96</xref>]. </p><p>A recent study evaluated the use of oral administration of rFeIFN-&#x003c9; for the treatment of eleven client-owned, naturally FIV-infected cats with clinical signs [<xref rid="B108-vetsci-02-00456" ref-type="bibr">108</xref>]. The treatment protocol was 10<sup>5</sup> U/cat PO q 24 h for 90 consecutive days, administered by the cats&#x02019; owners. A historical retrospective group was used as a control for comparison (10<sup>6</sup> U/kg SC q 24 h on five consecutive days for three cycles), but a placebo group was not included. Treatment with oral rFeIFN-&#x003c9; resulted in a significant improvement in clinical scores (e.g., oral lesions, coat appearance, body condition score, and ocular discharge) after treatment. In addition, there was no significant difference between the SC historical control group and the PO group, suggesting that oral administration of rFeIFN-&#x003c9; might be a viable and less expensive alternative [<xref rid="B109-vetsci-02-00456" ref-type="bibr">109</xref>]. In a recently published study that assessed viremia, provirus load, and blood cytokine profile in naturally FIV-infected cats treated with oral rFeIFN-&#x003c9; (10<sup>5</sup> U/cat PO q 24 h for 90 days) or with subcutaneous rFeIFN-&#x003c9; (10<sup>6</sup> U/cat SC q 24 h for 5 consecutive days in three courses), no change in the level of viremia or in most cytokine levels was found; a placebo control group was not included [<xref rid="B109-vetsci-02-00456" ref-type="bibr">109</xref>]. The fact that virus load remained unchanged but some clinical improvement was observed in earlier studies suggests that rFeIFN-&#x003c9; has an effect on secondary infections rather than on FIV itself [<xref rid="B94-vetsci-02-00456" ref-type="bibr">94</xref>]. As there are major differences in outcomes of the different studies on feline IFN-&#x003c9; in FIV-infected cats. Thus, a definitive conclusion cannot be drawn without additional randomized, placebo-controlled, and double-blinded studies that include a sufficiently high number of naturally FIV-infected cats.</p></sec></sec><sec id="sec10-vetsci-02-00456"><title>10. Conclusions</title><p>Unfortunately, the efficacy of antiviral compounds for the treatment of FIV in cats has been generally poor. The duration of treatment in many clinical trials was relatively short and might have been inadequate for infections with a long clinical course. In addition, it is difficult to compare treatment results of cats infected experimentally and kept under laboratory conditions and pet cats infected with field strains of FIV. Therefore, further well-designed double-blinded, placebo-controlled trials using antiviral drugs in naturally FIV-infected cats are needed to determine the efficacy and side effects of different antiviral compounds.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors did not receive a grant from any funding agency in the public, commercial, or non-profit-sectors for the preparation of this review article.</p></ack><notes><title>Author Contributions</title><p>Katrin Hartmann had the original idea for the review and draftet the manuscript together with Mich&#x000e8;le Bergmann and Anita Wooding. All authors revised and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that there is no conflict of interest.</p></notes><app-group><app id="app1-vetsci-02-00456"><title>Appendix</title><table-wrap id="vetsci-02-00456-t001" position="anchor"><object-id pub-id-type="pii">vetsci-02-00456-t001_Table A1</object-id><label>Table A1</label><caption><p>Treatment options (antiviral drugs) for FIV-infected cats (including EBM grades for judgment of the available efficacy data; EBM grades used according to the European Advisory Board of Cat Diseases (ABCD).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Efficacy <italic>In Vitro</italic></th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Efficacy <italic>in Vivo</italic></th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author&#x02019;s Personal Opinion</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ebm Level (I&#x02013;Iv)</th></tr></thead><tbody><tr><td colspan="4" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1"><italic><bold>Nucleoside Analogue&#x02014;Reverse Transcriptase Inhibitors</bold></italic></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zidovudine (AZT)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B27-vetsci-02-00456" ref-type="bibr">27</xref>,<xref rid="B14-vetsci-02-00456" ref-type="bibr">14</xref>,<xref rid="B16-vetsci-02-00456" ref-type="bibr">16</xref>,<xref rid="B17-vetsci-02-00456" ref-type="bibr">17</xref>,<xref rid="B18-vetsci-02-00456" ref-type="bibr">18</xref>,<xref rid="B19-vetsci-02-00456" ref-type="bibr">19</xref>,<xref rid="B20-vetsci-02-00456" ref-type="bibr">20</xref>,<xref rid="B22-vetsci-02-00456" ref-type="bibr">22</xref>,<xref rid="B23-vetsci-02-00456" ref-type="bibr">23</xref>,<xref rid="B24-vetsci-02-00456" ref-type="bibr">24</xref>,<xref rid="B25-vetsci-02-00456" ref-type="bibr">25</xref>,<xref rid="B26-vetsci-02-00456" ref-type="bibr">26</xref>,<xref rid="B38-vetsci-02-00456" ref-type="bibr">38</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B76-vetsci-02-00456" ref-type="bibr">76</xref>,<xref rid="B28-vetsci-02-00456" ref-type="bibr">28</xref>,<xref rid="B29-vetsci-02-00456" ref-type="bibr">29</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">effective in some cats (e.g., with stomatitis, neurological disorders)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stavudine (d4T)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B14-vetsci-02-00456" ref-type="bibr">14</xref>,<xref rid="B18-vetsci-02-00456" ref-type="bibr">18</xref>,<xref rid="B20-vetsci-02-00456" ref-type="bibr">20</xref>,<xref rid="B21-vetsci-02-00456" ref-type="bibr">21</xref>,<xref rid="B22-vetsci-02-00456" ref-type="bibr">22</xref>,<xref rid="B23-vetsci-02-00456" ref-type="bibr">23</xref>,<xref rid="B26-vetsci-02-00456" ref-type="bibr">26</xref>,<xref rid="B76-vetsci-02-00456" ref-type="bibr">76</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">possibly effective, but no data in cats available</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Didanosine (ddI)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B14-vetsci-02-00456" ref-type="bibr">14</xref>,<xref rid="B18-vetsci-02-00456" ref-type="bibr">18</xref>,<xref rid="B19-vetsci-02-00456" ref-type="bibr">19</xref>,<xref rid="B20-vetsci-02-00456" ref-type="bibr">20</xref>,<xref rid="B21-vetsci-02-00456" ref-type="bibr">21</xref>,<xref rid="B22-vetsci-02-00456" ref-type="bibr">22</xref>,<xref rid="B23-vetsci-02-00456" ref-type="bibr">23</xref>,<xref rid="B24-vetsci-02-00456" ref-type="bibr">24</xref>,<xref rid="B26-vetsci-02-00456" ref-type="bibr">26</xref>,<xref rid="B38-vetsci-02-00456" ref-type="bibr">38</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B39-vetsci-02-00456" ref-type="bibr">39</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">effective in one experimental study, but neurologic side effects</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zalcitabine (ddC)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B14-vetsci-02-00456" ref-type="bibr">14</xref>,<xref rid="B15-vetsci-02-00456" ref-type="bibr">15</xref>,<xref rid="B17-vetsci-02-00456" ref-type="bibr">17</xref>,<xref rid="B19-vetsci-02-00456" ref-type="bibr">19</xref>,<xref rid="B21-vetsci-02-00456" ref-type="bibr">21</xref>,<xref rid="B22-vetsci-02-00456" ref-type="bibr">22</xref>,<xref rid="B23-vetsci-02-00456" ref-type="bibr">23</xref>,<xref rid="B26-vetsci-02-00456" ref-type="bibr">26</xref>,<xref rid="B47-vetsci-02-00456" ref-type="bibr">47</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">possibly effective, but toxic</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lamivudine (3TC)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B16-vetsci-02-00456" ref-type="bibr">16</xref>,<xref rid="B17-vetsci-02-00456" ref-type="bibr">17</xref>,<xref rid="B20-vetsci-02-00456" ref-type="bibr">20</xref>,<xref rid="B21-vetsci-02-00456" ref-type="bibr">21</xref>,<xref rid="B22-vetsci-02-00456" ref-type="bibr">22</xref>,<xref rid="B23-vetsci-02-00456" ref-type="bibr">23</xref>,<xref rid="B76-vetsci-02-00456" ref-type="bibr">76</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">no [<xref rid="B41-vetsci-02-00456" ref-type="bibr">41</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not very effective, toxic in high dosages</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Emtricitabine (FTC)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B17-vetsci-02-00456" ref-type="bibr">17</xref>,<xref rid="B20-vetsci-02-00456" ref-type="bibr">20</xref>,<xref rid="B21-vetsci-02-00456" ref-type="bibr">21</xref>,<xref rid="B22-vetsci-02-00456" ref-type="bibr">22</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">possibly effective, but no data in cats available</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abacavir (ABC)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B20-vetsci-02-00456" ref-type="bibr">20</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">possibly effective but toxic</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td></tr><tr><td colspan="5" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1"><bold><italic>Nucleotide Analogue Reverse&#x02014;Transcriptase Inhibitors</italic></bold></td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adefovir (PMEA)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B28-vetsci-02-00456" ref-type="bibr">28</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">no [<xref rid="B47-vetsci-02-00456" ref-type="bibr">47</xref>,<xref rid="B48-vetsci-02-00456" ref-type="bibr">48</xref>,<xref rid="B49-vetsci-02-00456" ref-type="bibr">49</xref>,<xref rid="B50-vetsci-02-00456" ref-type="bibr">50</xref>,<xref rid="B51-vetsci-02-00456" ref-type="bibr">51</xref>,<xref rid="B52-vetsci-02-00456" ref-type="bibr">52</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">effective in some cats, but relatively toxic</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tenofovir (PMPA)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B25-vetsci-02-00456" ref-type="bibr">25</xref>,<xref rid="B35-vetsci-02-00456" ref-type="bibr">35</xref>,<xref rid="B45-vetsci-02-00456" ref-type="bibr">45</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">possibly effective, but also likely relatively toxic</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><italic>Non-Nucleoside Reverse Transcriptase Inhibitor</italic></bold></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suramin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">no</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">likely too toxic</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><italic>Nucleotide Synthesis Inhibitors</italic></bold></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Foscarnet (PFA)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B14-vetsci-02-00456" ref-type="bibr">14</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">effective <italic>in vitro</italic>, but too toxic</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ribavirin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B23-vetsci-02-00456" ref-type="bibr">23</xref>,<xref rid="B76-vetsci-02-00456" ref-type="bibr">76</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">possibly effective, but too toxic in cats</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><italic>Receptor Homologues/Antagonists</italic></bold></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plerixafor</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B82-vetsci-02-00456" ref-type="bibr">82</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B53-vetsci-02-00456" ref-type="bibr">53</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">some effect in a study in privately-owened cats (thus, can be considered as treatment)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><italic>Protease Inhibitors</italic></bold></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tipranavir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B85-vetsci-02-00456" ref-type="bibr">85</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">potentially effective, but no <italic>in vivo</italic> data available</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lopinavir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B85-vetsci-02-00456" ref-type="bibr">85</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">likely ineffective</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atazanavir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B85-vetsci-02-00456" ref-type="bibr">85</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">likely ineffective</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><italic>Integrase Inhibitors</italic></bold></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Raltegravir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B85-vetsci-02-00456" ref-type="bibr">85</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">possibly effective, but no data in FIV-infected cats available </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><italic>Interferons</italic></bold></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human interferon-&#x003b1; (IFN-&#x003b1;) SC high dose (10<sup>6</sup> U/kg q 24 h on five consecutive days)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B105-vetsci-02-00456" ref-type="bibr">105</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">no [<xref rid="B100-vetsci-02-00456" ref-type="bibr">100</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">likely ineffective</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SC intermediate dose (10<sup>5</sup> U/kg q 24 h for 90 days)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B105-vetsci-02-00456" ref-type="bibr">105</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">likely ineffective</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PO low dose (50 U/kg every 24 h for long-term period)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B105-vetsci-02-00456" ref-type="bibr">105</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B106-vetsci-02-00456" ref-type="bibr">106</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">some efficacy (most likely through effect on secondary infection)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Feline interferon-&#x003c9; (IFN-&#x003c9;) SC high dose 10<sup>6</sup> U/kg q 24 h on FIVe consecutive days</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B105-vetsci-02-00456" ref-type="bibr">105</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B107-vetsci-02-00456" ref-type="bibr">107</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">some improvement of clinical signs (most likely through effect on secondary infection)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PO intermediate dose 10<sup>5</sup> U/cat q 24 h for 90 consecutive days</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B105-vetsci-02-00456" ref-type="bibr">105</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B108-vetsci-02-00456" ref-type="bibr">108</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">potentially some efficacy (most likely through effect on secondary infection)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PO low dose 10<sup>5</sup> U/cat q 24 h for 90 consecutive days</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">yes [<xref rid="B105-vetsci-02-00456" ref-type="bibr">105</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nd</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">potentially effective (most likely through effect on secondary infection)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td></tr></tbody></table><table-wrap-foot><fn><p><italic>FIV</italic>, feline immunodeficiency virus; <italic>nd</italic>, not determined.</p><p><bold>EBM, evidence based medicine [<xref rid="B4-vetsci-02-00456" ref-type="bibr">4</xref>,<xref rid="B110-vetsci-02-00456" ref-type="bibr">110</xref>]:</bold></p><p>EBM grade I = This is the best evidence, comprising data obtained from properly designed, randomized controlled clinical trials in the target species (in this context cats).</p><p>EBM grade II = Data obtained from properly designed, randomized controlled studies in the target species with spontaneous disease in an experimental setting.</p><p>EBM grade III = Data based on non-randomized clinical trials, multiple case series, other experimental studies, and dramatic results from uncontrolled studies.</p><p>EBM grade IV = Expert opinion, case reports, studies in other species, pathophysiological justification.</p></fn></table-wrap-foot></table-wrap></app></app-group><ref-list><title>References</title><ref id="B1-vetsci-02-00456"><label>1.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gleich</surname><given-names>S.E.</given-names></name><name><surname>Krieger</surname><given-names>S.</given-names></name><name><surname>Hartmann</surname><given-names>K.</given-names></name></person-group>
<article-title>Prevalence of feline immunodeficiency virus and feline leukaemia virus among client-owned cats and risk factors for infection in germany</article-title>
<source>J. Feline Med. Surg.</source>
<year>2009</year>
<volume>11</volume>
<fpage>985</fpage>
<lpage>992</lpage>
<pub-id pub-id-type="doi">10.1016/j.jfms.2009.05.019</pub-id>
<?supplied-pmid 19616984?><pub-id pub-id-type="pmid">19616984</pub-id></element-citation></ref><ref id="B2-vetsci-02-00456"><label>2.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Addie</surname><given-names>D.D.</given-names></name><name><surname>Dennis</surname><given-names>J.M.</given-names></name><name><surname>Toth</surname><given-names>S.</given-names></name><name><surname>Callanan</surname><given-names>J.J.</given-names></name><name><surname>Reid</surname><given-names>S.</given-names></name><name><surname>Jarrett</surname><given-names>O.</given-names></name></person-group>
<article-title>Long-term impact on a closed household of pet cats of natural infection with feline coronavirus, feline leukaemia virus and feline immunodeficiency virus</article-title>
<source>Vet. Rec.</source>
<year>2000</year>
<volume>146</volume>
<fpage>419</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="doi">10.1136/vr.146.15.419</pub-id>
<?supplied-pmid 10811262?><pub-id pub-id-type="pmid">10811262</pub-id></element-citation></ref><ref id="B3-vetsci-02-00456"><label>3.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Levy</surname><given-names>J.</given-names></name><name><surname>Crawford</surname><given-names>C.</given-names></name><name><surname>Hartmann</surname><given-names>K.</given-names></name><name><surname>Hofmann-Lehmann</surname><given-names>R.</given-names></name><name><surname>Little</surname><given-names>S.</given-names></name><name><surname>Sundahl</surname><given-names>E.</given-names></name><name><surname>Thayer</surname><given-names>V.</given-names></name></person-group>
<article-title>2008 american association of feline practitioners&#x02019; feline retrovirus management guidelines</article-title>
<source>J. Feline Med. Surg.</source>
<year>2008</year>
<volume>10</volume>
<fpage>300</fpage>
<lpage>316</lpage>
<pub-id pub-id-type="doi">10.1016/j.jfms.2008.03.002</pub-id>
<?supplied-pmid 18455463?><pub-id pub-id-type="pmid">18455463</pub-id></element-citation></ref><ref id="B4-vetsci-02-00456"><label>4.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group>
<article-title>Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections</article-title>
<source>J. Med. Chem.</source>
<year>1995</year>
<volume>38</volume>
<fpage>2491</fpage>
<lpage>2517</lpage>
<pub-id pub-id-type="doi">10.1021/jm00014a001</pub-id>
<?supplied-pmid 7543152?><pub-id pub-id-type="pmid">7543152</pub-id></element-citation></ref><ref id="B5-vetsci-02-00456"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group>
<article-title>Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV</article-title>
<source>Int. J. Antimicrob. Agents</source>
<year>2009</year>
<volume>33</volume>
<fpage>307</fpage>
<lpage>320</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2008.10.010</pub-id>
<?supplied-pmid 19108994?><pub-id pub-id-type="pmid">19108994</pub-id></element-citation></ref><ref id="B6-vetsci-02-00456"><label>6.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>K.</given-names></name></person-group>
<article-title>Antiviral and immunomodulatory chemotherapy</article-title>
<source>Infectious Diseases of the Dog and Cat</source>
<edition>4th ed.</edition>
<person-group person-group-type="editor"><name><surname>Greene</surname><given-names>C.E.</given-names></name></person-group>
<publisher-name>Elsevier, Saunders</publisher-name>
<publisher-loc>St Louis, MO, USA</publisher-loc>
<year>2012</year>
<fpage>10</fpage>
<lpage>24</lpage>
</element-citation></ref><ref id="B7-vetsci-02-00456"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Auwerx</surname><given-names>J.</given-names></name><name><surname>Esnouf</surname><given-names>R.</given-names></name><name><surname>de Clercq</surname><given-names>E.</given-names></name><name><surname>Balzarini</surname><given-names>J.</given-names></name></person-group>
<article-title>Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors</article-title>
<source>Mol. Pharmacol.</source>
<year>2004</year>
<volume>65</volume>
<fpage>244</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="doi">10.1124/mol.65.1.244</pub-id>
<?supplied-pmid 14722257?><pub-id pub-id-type="pmid">14722257</pub-id></element-citation></ref><ref id="B8-vetsci-02-00456"><label>8.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mohammadi</surname><given-names>H.</given-names></name><name><surname>Bienzle</surname><given-names>D.</given-names></name></person-group>
<article-title>Pharmacological inhibition of feline immunodeficiency virus (FIV)</article-title>
<source>Viruses</source>
<year>2012</year>
<volume>4</volume>
<fpage>708</fpage>
<lpage>724</lpage>
<pub-id pub-id-type="doi">10.3390/v4050708</pub-id>
<?supplied-pmid 22754645?><pub-id pub-id-type="pmid">22754645</pub-id></element-citation></ref><ref id="B9-vetsci-02-00456"><label>9.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tressler</surname><given-names>R.</given-names></name><name><surname>Godfrey</surname><given-names>C.</given-names></name></person-group>
<article-title>NRTI backbone in HIV treatment: Will it remain relevant?</article-title>
<source>Drugs</source>
<year>2012</year>
<volume>72</volume>
<fpage>2051</fpage>
<lpage>2062</lpage>
<pub-id pub-id-type="doi">10.2165/11640830-000000000-00000</pub-id>
<?supplied-pmid 23083109?><pub-id pub-id-type="pmid">23083109</pub-id></element-citation></ref><ref id="B10-vetsci-02-00456"><label>10.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group>
<article-title>The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS)</article-title>
<source>Adv. Pharmacol.</source>
<year>2013</year>
<volume>67</volume>
<fpage>317</fpage>
<lpage>358</lpage>
<?supplied-pmid 23886005?><pub-id pub-id-type="pmid">23886005</pub-id></element-citation></ref><ref id="B11-vetsci-02-00456"><label>11.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horwitz</surname><given-names>J.P.</given-names></name><name><surname>Chua</surname><given-names>J.</given-names></name><name><surname>Noel</surname><given-names>M.</given-names></name></person-group>
<article-title>Nucleosides. V. The monomesylates of 1-(2'-deoxy-b-<sc>d</sc>-lyxofuranosyl)thymine</article-title>
<source>J. Org. Chem.</source>
<year>1964</year>
<volume>29</volume>
<fpage>2076</fpage>
<lpage>2078</lpage>
<pub-id pub-id-type="doi">10.1021/jo01030a546</pub-id>
</element-citation></ref><ref id="B12-vetsci-02-00456"><label>12.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mitsuya</surname><given-names>H.</given-names></name><name><surname>Weinhold</surname><given-names>K.J.</given-names></name><name><surname>Furman</surname><given-names>P.A.</given-names></name><name><surname>St Clair</surname><given-names>M.H.</given-names></name><name><surname>Lehrman</surname><given-names>S.N.</given-names></name><name><surname>Gallo</surname><given-names>R.C.</given-names></name><name><surname>Bolognesi</surname><given-names>D.</given-names></name><name><surname>Barry</surname><given-names>D.W.</given-names></name><name><surname>Broder</surname><given-names>S.</given-names></name></person-group>
<article-title>3'-azido-3'-deoxythymidine (BW a509u): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type iii/lymphadenopathy-associated virus <italic>in vitro</italic></article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>1985</year>
<volume>82</volume>
<fpage>7096</fpage>
<lpage>7100</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.82.20.7096</pub-id>
<?supplied-pmid 2413459?><pub-id pub-id-type="pmid">2413459</pub-id></element-citation></ref><ref id="B13-vetsci-02-00456"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ezzell</surname><given-names>C.</given-names></name></person-group>
<article-title>Azt given the green light for clinical treatment of AIDS</article-title>
<source>Nature</source>
<year>1987</year>
<volume>326</volume>
<fpage>430</fpage>
<?supplied-pmid 3470603?><pub-id pub-id-type="pmid">3470603</pub-id></element-citation></ref><ref id="B14-vetsci-02-00456"><label>14.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gobert</surname><given-names>J.M.</given-names></name><name><surname>Remington</surname><given-names>K.M.</given-names></name><name><surname>Zhu</surname><given-names>Y.Q.</given-names></name><name><surname>North</surname><given-names>T.W.</given-names></name></person-group>
<article-title>Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>1994</year>
<volume>38</volume>
<fpage>861</fpage>
<lpage>864</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.38.4.861</pub-id>
<?supplied-pmid 8031060?><pub-id pub-id-type="pmid">8031060</pub-id></element-citation></ref><ref id="B15-vetsci-02-00456"><label>15.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>K.</given-names></name><name><surname>Donath</surname><given-names>A.</given-names></name><name><surname>Kraft</surname><given-names>W.</given-names></name></person-group>
<article-title>AZT in the treatment of feline immunodeficiency virus infection: Part 1</article-title>
<source>Feline Pract</source>
<year>1995</year>
<volume>23</volume>
<fpage>16</fpage>
<lpage>21</lpage>
</element-citation></ref><ref id="B16-vetsci-02-00456"><label>16.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bisset</surname><given-names>L.R.</given-names></name><name><surname>Lutz</surname><given-names>H.</given-names></name><name><surname>Boni</surname><given-names>J.</given-names></name><name><surname>Hofmann-Lehmann</surname><given-names>R.</given-names></name><name><surname>Luthy</surname><given-names>R.</given-names></name><name><surname>Schupbach</surname><given-names>J.</given-names></name></person-group>
<article-title>Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing <italic>in vitro</italic> FIV replication</article-title>
<source>Antivir. Res.</source>
<year>2002</year>
<volume>53</volume>
<fpage>35</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="doi">10.1016/S0166-3542(01)00190-5</pub-id>
<pub-id pub-id-type="pmid">11684314</pub-id></element-citation></ref><ref id="B17-vetsci-02-00456"><label>17.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McCrackin Stevenson</surname><given-names>M.A.</given-names></name><name><surname>McBroom</surname><given-names>D.G.</given-names></name></person-group>
<article-title><italic>In vitro</italic> characterization of FIV-pPPR, a pathogenic molecular clone of feline immunodeficiency virus, and two drug-resistant pol gene mutants</article-title>
<source>Am. J. Vet. Res.</source>
<year>2001</year>
<volume>62</volume>
<fpage>588</fpage>
<lpage>594</lpage>
<pub-id pub-id-type="doi">10.2460/ajvr.2001.62.588</pub-id>
<?supplied-pmid 11327469?><pub-id pub-id-type="pmid">11327469</pub-id></element-citation></ref><ref id="B18-vetsci-02-00456"><label>18.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Remington</surname><given-names>K.M.</given-names></name><name><surname>Chesebro</surname><given-names>B.</given-names></name><name><surname>Wehrly</surname><given-names>K.</given-names></name><name><surname>Pedersen</surname><given-names>N.C.</given-names></name><name><surname>North</surname><given-names>T.W.</given-names></name></person-group>
<article-title>Mutants of feline immunodeficiency virus resistant to 3&#x02032;-azido-3&#x02032;-deoxythymidine</article-title>
<source>J. Virol.</source>
<year>1991</year>
<volume>65</volume>
<fpage>308</fpage>
<lpage>312</lpage>
<?supplied-pmid 1845891?><pub-id pub-id-type="pmid">1845891</pub-id></element-citation></ref><ref id="B19-vetsci-02-00456"><label>19.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Remington</surname><given-names>K.M.</given-names></name><name><surname>Zhu</surname><given-names>Y.Q.</given-names></name><name><surname>Phillips</surname><given-names>T.R.</given-names></name><name><surname>North</surname><given-names>T.W.</given-names></name></person-group>
<article-title>Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase</article-title>
<source>J. Virol.</source>
<year>1994</year>
<volume>68</volume>
<fpage>632</fpage>
<lpage>637</lpage>
<?supplied-pmid 7507182?><pub-id pub-id-type="pmid">7507182</pub-id></element-citation></ref><ref id="B20-vetsci-02-00456"><label>20.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>A.M.</given-names></name><name><surname>McCrackin</surname><given-names>M.A.</given-names></name><name><surname>Schinazi</surname><given-names>R.F.</given-names></name><name><surname>Hill</surname><given-names>P.B.</given-names></name><name><surname>Vahlenkamp</surname><given-names>T.W.</given-names></name><name><surname>Tompkins</surname><given-names>M.B.</given-names></name><name><surname>Hartmann</surname><given-names>K.</given-names></name></person-group>
<article-title>Antiviral efficacy of nine nucleoside reverse transcriptase inhibitors against feline immunodeficiency virus in feline peripheral blood mononuclear cells</article-title>
<source>Am. J. Vet. Res.</source>
<year>2014</year>
<volume>75</volume>
<fpage>273</fpage>
<lpage>281</lpage>
<pub-id pub-id-type="doi">10.2460/ajvr.75.3.273</pub-id>
<?supplied-pmid 24564313?><pub-id pub-id-type="pmid">24564313</pub-id></element-citation></ref><ref id="B21-vetsci-02-00456"><label>21.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>R.A.</given-names></name><name><surname>Remington</surname><given-names>K.M.</given-names></name><name><surname>Lloyd</surname><given-names>R.M.</given-names><suffix>Jr.</suffix></name><name><surname>Schinazi</surname><given-names>R.F.</given-names></name><name><surname>North</surname><given-names>T.W.</given-names></name></person-group>
<article-title>A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides</article-title>
<source>J. Virol.</source>
<year>1997</year>
<volume>71</volume>
<fpage>2357</fpage>
<lpage>2362</lpage>
<?supplied-pmid 9032372?><pub-id pub-id-type="pmid">9032372</pub-id></element-citation></ref><ref id="B22-vetsci-02-00456"><label>22.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>R.A.</given-names></name><name><surname>Remington</surname><given-names>K.M.</given-names></name><name><surname>Preston</surname><given-names>B.D.</given-names></name><name><surname>Schinazi</surname><given-names>R.F.</given-names></name><name><surname>North</surname><given-names>T.W.</given-names></name></person-group>
<article-title>A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine</article-title>
<source>J. Virol.</source>
<year>1998</year>
<volume>72</volume>
<fpage>2335</fpage>
<lpage>2340</lpage>
<?supplied-pmid 9499094?><pub-id pub-id-type="pmid">9499094</pub-id></element-citation></ref><ref id="B23-vetsci-02-00456"><label>23.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smyth</surname><given-names>N.R.</given-names></name><name><surname>McCracken</surname><given-names>C.</given-names></name><name><surname>Gaskell</surname><given-names>R.M.</given-names></name><name><surname>Cameron</surname><given-names>J.M.</given-names></name><name><surname>Coates</surname><given-names>J.A.</given-names></name><name><surname>Gaskell</surname><given-names>C.J.</given-names></name><name><surname>Hart</surname><given-names>C.A.</given-names></name><name><surname>Bennett</surname><given-names>M.</given-names></name></person-group>
<article-title>Susceptibility in cell culture of feline immunodeficiency virus to eighteen antiviral agents</article-title>
<source>J. Antimicrob. Chemother.</source>
<year>1994</year>
<volume>34</volume>
<fpage>589</fpage>
<lpage>594</lpage>
<pub-id pub-id-type="doi">10.1093/jac/34.4.589</pub-id>
<?supplied-pmid 7532645?><pub-id pub-id-type="pmid">7532645</pub-id></element-citation></ref><ref id="B24-vetsci-02-00456"><label>24.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tanabe-Tochikura</surname><given-names>A.</given-names></name><name><surname>Tochikura</surname><given-names>T.S.</given-names></name><name><surname>Blakeslee</surname><given-names>J.R.</given-names><suffix>Jr.</suffix></name><name><surname>Olsen</surname><given-names>R.G.</given-names></name><name><surname>Mathes</surname><given-names>L.E.</given-names></name></person-group>
<article-title>Anti-human immunodeficiency virus (HIV) agents are also potent and selective inhibitors of feline immunodeficiency virus (FIV)-induced cytopathic effect: Development of a new method for screening of anti-FIV substances <italic>in vitro</italic></article-title>
<source>Antivir. Res.</source>
<year>1992</year>
<volume>19</volume>
<fpage>161</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="doi">10.1016/0166-3542(92)90075-G</pub-id>
<pub-id pub-id-type="pmid">1332602</pub-id></element-citation></ref><ref id="B25-vetsci-02-00456"><label>25.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vahlenkamp</surname><given-names>T.W.</given-names></name><name><surname>De Ronde</surname><given-names>A.</given-names></name><name><surname>Balzarini</surname><given-names>J.</given-names></name><name><surname>Naesens</surname><given-names>L.</given-names></name><name><surname>De Clercq</surname><given-names>E.</given-names></name><name><surname>van Eijk</surname><given-names>M.J.</given-names></name><name><surname>Horzinek</surname><given-names>M.C.</given-names></name><name><surname>Egberink</surname><given-names>H.F.</given-names></name></person-group>
<article-title>(r-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>1995</year>
<volume>39</volume>
<fpage>746</fpage>
<lpage>749</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.39.3.746</pub-id>
<?supplied-pmid 7793884?><pub-id pub-id-type="pmid">7793884</pub-id></element-citation></ref><ref id="B26-vetsci-02-00456"><label>26.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y.Q.</given-names></name><name><surname>Remington</surname><given-names>K.M.</given-names></name><name><surname>North</surname><given-names>T.W.</given-names></name></person-group>
<article-title>Mutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>1996</year>
<volume>40</volume>
<fpage>1983</fpage>
<lpage>1987</lpage>
<?supplied-pmid 8878567?><pub-id pub-id-type="pmid">8878567</pub-id></element-citation></ref><ref id="B27-vetsci-02-00456"><label>27.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>North</surname><given-names>T.W.</given-names></name><name><surname>North</surname><given-names>G.L.</given-names></name><name><surname>Pedersen</surname><given-names>N.C.</given-names></name></person-group>
<article-title>Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>1989</year>
<volume>33</volume>
<fpage>915</fpage>
<lpage>919</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.33.6.915</pub-id>
<?supplied-pmid 2475068?><pub-id pub-id-type="pmid">2475068</pub-id></element-citation></ref><ref id="B28-vetsci-02-00456"><label>28.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>K.</given-names></name><name><surname>Donath</surname><given-names>A.</given-names></name><name><surname>Kraft</surname><given-names>W.</given-names></name></person-group>
<article-title>Azt in the treatment of feline immunodeficiency virus infection: Part 2</article-title>
<source>Feline Pract.</source>
<year>1995</year>
<volume>23</volume>
<fpage>13</fpage>
<lpage>20</lpage>
</element-citation></ref><ref id="B29-vetsci-02-00456"><label>29.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>K.</given-names></name></person-group>
<article-title>Feline immunodeficiency virus infection: An overview</article-title>
<source>Vet. J.</source>
<year>1998</year>
<volume>155</volume>
<fpage>123</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1016/S1090-0233(98)80008-7</pub-id>
<pub-id pub-id-type="pmid">9564266</pub-id></element-citation></ref><ref id="B30-vetsci-02-00456"><label>30.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>August</surname><given-names>E.M.</given-names></name><name><surname>Marongiu</surname><given-names>M.E.</given-names></name><name><surname>Lin</surname><given-names>T.S.</given-names></name><name><surname>Prusoff</surname><given-names>W.H.</given-names></name></person-group>
<article-title>Initial studies on the cellular pharmacology of 3'-deoxythymidin-2'-ene (D4T): A potent and selective inhibitor of human immunodeficiency virus</article-title>
<source>Biochem. Pharmacol.</source>
<year>1988</year>
<volume>37</volume>
<fpage>4419</fpage>
<lpage>4422</lpage>
<pub-id pub-id-type="doi">10.1016/0006-2952(88)90655-7</pub-id>
<pub-id pub-id-type="pmid">2849444</pub-id></element-citation></ref><ref id="B31-vetsci-02-00456"><label>31.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baba</surname><given-names>M.</given-names></name><name><surname>Pauwels</surname><given-names>R.</given-names></name><name><surname>Herdewijn</surname><given-names>P.</given-names></name><name><surname>de Clercq</surname><given-names>E.</given-names></name><name><surname>Desmyter</surname><given-names>J.</given-names></name><name><surname>Vandeputte</surname><given-names>M.</given-names></name></person-group>
<article-title>Both 2&#x02032;,3&#x02032;-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication <italic>in vitro</italic></article-title>
<source>Biochem. Biophys. Res. Commun.</source>
<year>1987</year>
<volume>142</volume>
<fpage>128</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1016/0006-291X(87)90460-8</pub-id>
<pub-id pub-id-type="pmid">3028398</pub-id></element-citation></ref><ref id="B32-vetsci-02-00456"><label>32.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Balzarini</surname><given-names>J.</given-names></name><name><surname>Kang</surname><given-names>G.J.</given-names></name><name><surname>Dalal</surname><given-names>M.</given-names></name><name><surname>Herdewijn</surname><given-names>P.</given-names></name><name><surname>de Clercq</surname><given-names>E.</given-names></name><name><surname>Broder</surname><given-names>S.</given-names></name><name><surname>Johns</surname><given-names>D.G.</given-names></name></person-group>
<article-title>The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2&#x02032;,3&#x02032;-didehydro-2',3'-dideoxyribonucleosides: A comparison with their parental 2',3'-dideoxyribonucleosides</article-title>
<source>Mol. Pharmacol.</source>
<year>1987</year>
<volume>32</volume>
<fpage>162</fpage>
<lpage>167</lpage>
<?supplied-pmid 3648476?><pub-id pub-id-type="pmid">3648476</pub-id></element-citation></ref><ref id="B33-vetsci-02-00456"><label>33.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>T.S.</given-names></name><name><surname>Schinazi</surname><given-names>R.F.</given-names></name><name><surname>Prusoff</surname><given-names>W.H.</given-names></name></person-group>
<article-title>Potent and selective <italic>in vitro</italic> activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus</article-title>
<source>Biochem. Pharmacol.</source>
<year>1987</year>
<volume>36</volume>
<fpage>2713</fpage>
<lpage>2718</lpage>
<?supplied-pmid 2443141?><pub-id pub-id-type="pmid">2443141</pub-id></element-citation></ref><ref id="B34-vetsci-02-00456"><label>34.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martin</surname><given-names>J.C.</given-names></name><name><surname>Hitchcock</surname><given-names>M.J.</given-names></name><name><surname>de Clercq</surname><given-names>E.</given-names></name><name><surname>Prusoff</surname><given-names>W.H.</given-names></name></person-group>
<article-title>Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: A brief history of stavudine (D4T) and its comparison with other dideoxynucleosides</article-title>
<source>Antivir. Res.</source>
<year>2010</year>
<volume>85</volume>
<fpage>34</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1016/j.antiviral.2009.10.006</pub-id>
<?supplied-pmid 19854224?><pub-id pub-id-type="pmid">19854224</pub-id></element-citation></ref><ref id="B35-vetsci-02-00456"><label>35.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Balzarini</surname><given-names>J.</given-names></name><name><surname>Egberink</surname><given-names>H.</given-names></name><name><surname>Hartmann</surname><given-names>K.</given-names></name><name><surname>Cahard</surname><given-names>D.</given-names></name><name><surname>Vahlenkamp</surname><given-names>T.</given-names></name><name><surname>Thormar</surname><given-names>H.</given-names></name><name><surname>de Clercq</surname><given-names>E.</given-names></name><name><surname>McGuigan</surname><given-names>C.</given-names></name></person-group>
<article-title>Antiretrovirus specificity and intracellular metabolism of 2',3' -didehydro-2',3'-dideoxythymidine and its 5'-monophosphate triester prodrug SO324</article-title>
<source>Mol. Pharmacol.</source>
<year>1996</year>
<volume>50</volume>
<fpage>1207</fpage>
<lpage>1213</lpage>
<?supplied-pmid 8913352?><pub-id pub-id-type="pmid">8913352</pub-id></element-citation></ref><ref id="B36-vetsci-02-00456"><label>36.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tavares</surname><given-names>L.</given-names></name><name><surname>Roneker</surname><given-names>C.</given-names></name><name><surname>Postie</surname><given-names>L.</given-names></name><name><surname>de Noronha</surname><given-names>F.</given-names></name></person-group>
<article-title>Testing of nucleoside analogues in cats infected with feline leukemia virus: A model</article-title>
<source>Intervirology</source>
<year>1989</year>
<volume>30</volume>
<fpage>26</fpage>
<lpage>35</lpage>
<?supplied-pmid 2540111?><pub-id pub-id-type="pmid">2540111</pub-id></element-citation></ref><ref id="B37-vetsci-02-00456"><label>37.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mitsuya</surname><given-names>H.</given-names></name><name><surname>Broder</surname><given-names>S.</given-names></name></person-group>
<article-title>Inhibition of the <italic>in vitro</italic> infectivity and cytopathic effect of human T-lymphotrophic virus type iii/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>1986</year>
<volume>83</volume>
<fpage>1911</fpage>
<lpage>1915</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.83.6.1911</pub-id>
<?supplied-pmid 3006077?><pub-id pub-id-type="pmid">3006077</pub-id></element-citation></ref><ref id="B38-vetsci-02-00456"><label>38.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Medlin</surname><given-names>H.K.</given-names></name><name><surname>Zhu</surname><given-names>Y.Q.</given-names></name><name><surname>Remington</surname><given-names>K.M.</given-names></name><name><surname>Phillips</surname><given-names>T.R.</given-names></name><name><surname>North</surname><given-names>T.W.</given-names></name></person-group>
<article-title>Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>1996</year>
<volume>40</volume>
<fpage>953</fpage>
<lpage>957</lpage>
<?supplied-pmid 8849258?><pub-id pub-id-type="pmid">8849258</pub-id></element-citation></ref><ref id="B39-vetsci-02-00456"><label>39.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Antony</surname><given-names>J.M.</given-names></name><name><surname>Martinez</surname><given-names>J.A.</given-names></name><name><surname>Glerum</surname><given-names>D.M.</given-names></name><name><surname>Brussee</surname><given-names>V.</given-names></name><name><surname>Hoke</surname><given-names>A.</given-names></name><name><surname>Zochodne</surname><given-names>D.</given-names></name><name><surname>Power</surname><given-names>C.</given-names></name></person-group>
<article-title>Didanosine causes sensory neuropathy in an HIV/AIDS animal model: Impaired mitochondrial and neurotrophic factor gene expression</article-title>
<source>Brain: J. Neurol.</source>
<year>2007</year>
<volume>130</volume>
<fpage>2011</fpage>
<lpage>2023</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awm148</pub-id>
<?supplied-pmid 17616550?><pub-id pub-id-type="pmid">17616550</pub-id></element-citation></ref><ref id="B40-vetsci-02-00456"><label>40.</label><element-citation publication-type="gov">
<person-group person-group-type="author"><collab>FDA</collab></person-group>
<article-title>Antiretroviral Drugs Used in the Treatment of Human Immunodeficiency Virus Infection</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.Fda.Gov/forpatients/illness/HIVAIDS/treatment/ucm118915.Htm">http://www.Fda.Gov/forpatients/illness/HIVAIDS/treatment/ucm118915.Htm</ext-link></comment>
<date-in-citation>(accessed on 14 July 2015)</date-in-citation>
</element-citation></ref><ref id="B41-vetsci-02-00456"><label>41.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arai</surname><given-names>M.</given-names></name><name><surname>Earl</surname><given-names>D.D.</given-names></name><name><surname>Yamamoto</surname><given-names>J.K.</given-names></name></person-group>
<article-title>Is AZT/3TC therapy effective against FIV infection or immunopathogenesis?</article-title>
<source>Vet. Immunol. Immunopathol.</source>
<year>2002</year>
<volume>85</volume>
<fpage>189</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-2427(01)00426-3</pub-id>
<pub-id pub-id-type="pmid">11943320</pub-id></element-citation></ref><ref id="B42-vetsci-02-00456"><label>42.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ravichandran</surname><given-names>S.</given-names></name><name><surname>Veerasamy</surname><given-names>R.</given-names></name><name><surname>Raman</surname><given-names>S.</given-names></name><name><surname>Krishnan</surname><given-names>P.N.</given-names></name><name><surname>Agraval</surname><given-names>R.K.</given-names></name></person-group>
<article-title>An overview on HIV-1 reverse transcriptase inhibitors</article-title>
<source>Dig. J. Nanomater. Biostruct.</source>
<year>2008</year>
<fpage>171</fpage>
<lpage>187</lpage>
</element-citation></ref><ref id="B43-vetsci-02-00456"><label>43.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cihlar</surname><given-names>T.</given-names></name><name><surname>Ray</surname><given-names>A.S.</given-names></name></person-group>
<article-title>Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine</article-title>
<source>Antivir. Res.</source>
<year>2010</year>
<volume>85</volume>
<fpage>39</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1016/j.antiviral.2009.09.014</pub-id>
<?supplied-pmid 19887088?><pub-id pub-id-type="pmid">19887088</pub-id></element-citation></ref><ref id="B44-vetsci-02-00456"><label>44.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group>
<article-title>Acyclic nucleoside phosphonates: Past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: The phosphonate bridge</article-title>
<source>Biochem. Pharmacol.</source>
<year>2007</year>
<volume>73</volume>
<fpage>911</fpage>
<lpage>922</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2006.09.014</pub-id>
<?supplied-pmid 17045247?><pub-id pub-id-type="pmid">17045247</pub-id></element-citation></ref><ref id="B45-vetsci-02-00456"><label>45.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Balzarini</surname><given-names>J.</given-names></name><name><surname>Vahlenkamp</surname><given-names>T.</given-names></name><name><surname>Egberink</surname><given-names>H.</given-names></name><name><surname>Hartmann</surname><given-names>K.</given-names></name><name><surname>Witvrouw</surname><given-names>M.</given-names></name><name><surname>Pannecouque</surname><given-names>C.</given-names></name><name><surname>Casara</surname><given-names>P.</given-names></name><name><surname>Nave</surname><given-names>J.F.</given-names></name><name><surname>de Clercq</surname><given-names>E.</given-names></name></person-group>
<article-title>Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and mdl 74,968] in cell cultures and murine sarcoma virus-infected newborn nmri mice</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>1997</year>
<volume>41</volume>
<fpage>611</fpage>
<lpage>616</lpage>
<?supplied-pmid 9056002?><pub-id pub-id-type="pmid">9056002</pub-id></element-citation></ref><ref id="B46-vetsci-02-00456"><label>46.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Balzarini</surname><given-names>J.</given-names></name><name><surname>Naesens</surname><given-names>L.</given-names></name><name><surname>Slachmuylders</surname><given-names>J.</given-names></name><name><surname>Niphuis</surname><given-names>H.</given-names></name><name><surname>Rosenberg</surname><given-names>I.</given-names></name><name><surname>Holy</surname><given-names>A.</given-names></name><name><surname>Schellekens</surname><given-names>H.</given-names></name><name><surname>de Clercq</surname><given-names>E.</given-names></name></person-group>
<article-title>9-(2-phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication <italic>in vitro</italic> and simian immunodeficiency virus infection in Rhesus monkeys</article-title>
<source>AIDS</source>
<year>1991</year>
<volume>5</volume>
<fpage>21</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1097/00002030-199101000-00003</pub-id>
<?supplied-pmid 2059358?><pub-id pub-id-type="pmid">2059358</pub-id></element-citation></ref><ref id="B47-vetsci-02-00456"><label>47.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>K.</given-names></name><name><surname>Donath</surname><given-names>A.</given-names></name><name><surname>Beer</surname><given-names>B.</given-names></name><name><surname>Egberink</surname><given-names>H.F.</given-names></name><name><surname>Horzinek</surname><given-names>M.C.</given-names></name><name><surname>Lutz</surname><given-names>H.</given-names></name><name><surname>Hoffmann-Fezer</surname><given-names>G.</given-names></name><name><surname>Thum</surname><given-names>I.</given-names></name><name><surname>Thefeld</surname><given-names>S.</given-names></name></person-group>
<article-title>Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FELV seropositive cats with clinical symptoms</article-title>
<source>Vet. Immunol. Immunopathol.</source>
<year>1992</year>
<volume>35</volume>
<fpage>167</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="doi">10.1016/0165-2427(92)90129-E</pub-id>
<pub-id pub-id-type="pmid">1363008</pub-id></element-citation></ref><ref id="B48-vetsci-02-00456"><label>48.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Egberink</surname><given-names>H.</given-names></name><name><surname>Borst</surname><given-names>M.</given-names></name><name><surname>Niphuis</surname><given-names>H.</given-names></name><name><surname>Balzarini</surname><given-names>J.</given-names></name><name><surname>Neu</surname><given-names>H.</given-names></name><name><surname>Schellekens</surname><given-names>H.</given-names></name><name><surname>de Clercq</surname><given-names>E.</given-names></name><name><surname>Horzinek</surname><given-names>M.</given-names></name><name><surname>Koolen</surname><given-names>M.</given-names></name></person-group>
<article-title>Suppression of feline immunodeficiency virus infection <italic>in vivo</italic> by 9-(2-phosphonomethoxyethyl)adenine</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>1990</year>
<volume>87</volume>
<fpage>3087</fpage>
<lpage>3091</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.87.8.3087</pub-id>
<?supplied-pmid 2158102?><pub-id pub-id-type="pmid">2158102</pub-id></element-citation></ref><ref id="B49-vetsci-02-00456"><label>49.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>K.</given-names></name></person-group>
<article-title>Clinical aspects of feline retroviruses: A review</article-title>
<source>Viruses</source>
<year>2012</year>
<volume>4</volume>
<fpage>2684</fpage>
<lpage>2710</lpage>
<pub-id pub-id-type="doi">10.3390/v4112684</pub-id>
<?supplied-pmid 23202500?><pub-id pub-id-type="pmid">23202500</pub-id></element-citation></ref><ref id="B50-vetsci-02-00456"><label>50.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>K.</given-names></name><name><surname>Kuffer</surname><given-names>M.</given-names></name><name><surname>Balzarini</surname><given-names>J.</given-names></name><name><surname>Naesens</surname><given-names>L.</given-names></name><name><surname>Goldberg</surname><given-names>M.</given-names></name><name><surname>Erfle</surname><given-names>V.</given-names></name><name><surname>Goebel</surname><given-names>F.D.</given-names></name><name><surname>de Clercq</surname><given-names>E.</given-names></name><name><surname>Jindrich</surname><given-names>J.</given-names></name><name><surname>Holy</surname><given-names>A.</given-names></name><etal/></person-group>
<article-title>Efficacy of the acyclic nucleoside phosphonates (S)-9-(3-fluoro-2-phosphonylmethoxypropyl)adenine (FPMPA) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against feline immunodeficiency virus</article-title>
<source>J. Acquir. Immune Deficiency Syndr. Hum. Retrovirol.</source>
<year>1998</year>
<volume>17</volume>
<fpage>120</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="doi">10.1097/00042560-199802010-00004</pub-id>
</element-citation></ref><ref id="B51-vetsci-02-00456"><label>51.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuffer</surname><given-names>M.</given-names></name><name><surname>Balzarini</surname><given-names>J.</given-names></name><name><surname>Rolinski</surname><given-names>B.</given-names></name><name><surname>Goebel</surname><given-names>F.</given-names></name><name><surname>Erfle</surname><given-names>V.</given-names></name><name><surname>Goldberg</surname><given-names>M.</given-names></name><name><surname>Hartmann</surname><given-names>K.</given-names></name></person-group>
<article-title>comparative investigation of the efficacy of two nucleocapsid analogs in FIV infected cats</article-title>
<source>Tierarztliche Praxis Ausgabe K, Kleintiere/Heimtiere</source>
<year>1997</year>
<volume>25</volume>
<fpage>671</fpage>
<lpage>677</lpage>
<?supplied-pmid 9459835?><pub-id pub-id-type="pmid">9459835</pub-id></element-citation></ref><ref id="B52-vetsci-02-00456"><label>52.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Philpott</surname><given-names>M.S.</given-names></name><name><surname>Ebner</surname><given-names>J.P.</given-names></name><name><surname>Hoover</surname><given-names>E.A.</given-names></name></person-group>
<article-title>Evaluation of 9-(2-phosphonylmethoxyethyl) adenine therapy for feline immunodeficiency virus using a quantitative polymerase chain reaction</article-title>
<source>Vet. Immunol. Immunopathol.</source>
<year>1992</year>
<volume>35</volume>
<fpage>155</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="doi">10.1016/0165-2427(92)90128-D</pub-id>
<pub-id pub-id-type="pmid">1337395</pub-id></element-citation></ref><ref id="B53-vetsci-02-00456"><label>53.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>K.</given-names></name><name><surname>Stengel</surname><given-names>C.</given-names></name><name><surname>Klein</surname><given-names>D.</given-names></name><name><surname>Egberink</surname><given-names>H.</given-names></name><name><surname>Balzarini</surname><given-names>J.</given-names></name></person-group>
<article-title>Efficacy and adverse effects of the antiviral compound plerixafor in feline immunodeficiency virus-infected cats</article-title>
<source>J. Vet. Intern. Med./Am. Coll. Vet. Intern. Med.</source>
<year>2012</year>
<volume>26</volume>
<fpage>483</fpage>
<lpage>490</lpage>
<pub-id pub-id-type="doi">10.1111/j.1939-1676.2012.00904.x</pub-id>
<?supplied-pmid 22551322?><pub-id pub-id-type="pmid">22551322</pub-id></element-citation></ref><ref id="B54-vetsci-02-00456"><label>54.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Balzarini</surname><given-names>J.</given-names></name><name><surname>Aquaro</surname><given-names>S.</given-names></name><name><surname>Perno</surname><given-names>C.F.</given-names></name><name><surname>Witvrouw</surname><given-names>M.</given-names></name><name><surname>Holy</surname><given-names>A.</given-names></name><name><surname>de Clercq</surname><given-names>E.</given-names></name></person-group>
<article-title>Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems</article-title>
<source>Biochem. Biophys. Res. Commun.</source>
<year>1996</year>
<volume>219</volume>
<fpage>337</fpage>
<lpage>341</lpage>
<pub-id pub-id-type="doi">10.1006/bbrc.1996.0234</pub-id>
<?supplied-pmid 8604988?><pub-id pub-id-type="pmid">8604988</pub-id></element-citation></ref><ref id="B55-vetsci-02-00456"><label>55.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xia</surname><given-names>Q.</given-names></name><name><surname>Radzio</surname><given-names>J.</given-names></name><name><surname>Anderson</surname><given-names>K.S.</given-names></name><name><surname>Sluis-Cremer</surname><given-names>N.</given-names></name></person-group>
<article-title>Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses</article-title>
<source>Protein Sci.</source>
<year>2007</year>
<volume>16</volume>
<fpage>1728</fpage>
<lpage>1737</lpage>
<pub-id pub-id-type="doi">10.1110/ps.072829007</pub-id>
<?supplied-pmid 17656585?><pub-id pub-id-type="pmid">17656585</pub-id></element-citation></ref><ref id="B56-vetsci-02-00456"><label>56.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Das</surname><given-names>K.</given-names></name><name><surname>Martinez</surname><given-names>S.E.</given-names></name><name><surname>Bauman</surname><given-names>J.D.</given-names></name><name><surname>Arnold</surname><given-names>E.</given-names></name></person-group>
<article-title>HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism</article-title>
<source>Nat. Struct. Mol. Biol.</source>
<year>2012</year>
<volume>19</volume>
<fpage>253</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="doi">10.1038/nsmb.2223</pub-id>
<?supplied-pmid 22266819?><pub-id pub-id-type="pmid">22266819</pub-id></element-citation></ref><ref id="B57-vetsci-02-00456"><label>57.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Auwerx</surname><given-names>J.</given-names></name><name><surname>North</surname><given-names>T.W.</given-names></name><name><surname>Preston</surname><given-names>B.D.</given-names></name><name><surname>Klarmann</surname><given-names>G.J.</given-names></name><name><surname>De Clercq</surname><given-names>E.</given-names></name><name><surname>Balzarini</surname><given-names>J.</given-names></name></person-group>
<article-title>Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: Role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors</article-title>
<source>Mol. Pharmacol.</source>
<year>2002</year>
<volume>61</volume>
<fpage>400</fpage>
<lpage>406</lpage>
<pub-id pub-id-type="doi">10.1124/mol.61.2.400</pub-id>
<?supplied-pmid 11809865?><pub-id pub-id-type="pmid">11809865</pub-id></element-citation></ref><ref id="B58-vetsci-02-00456"><label>58.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garcia-Schurmann</surname><given-names>J.M.</given-names></name><name><surname>Schulze</surname><given-names>H.</given-names></name><name><surname>Haupt</surname><given-names>G.</given-names></name><name><surname>Pastor</surname><given-names>J.</given-names></name><name><surname>Allolio</surname><given-names>B.</given-names></name><name><surname>Senge</surname><given-names>T.</given-names></name></person-group>
<article-title>Suramin treatment in hormone- and chemotherapy-refractory prostate cancer</article-title>
<source>Urology</source>
<year>1999</year>
<volume>53</volume>
<fpage>535</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="doi">10.1016/S0090-4295(98)00544-5</pub-id>
<pub-id pub-id-type="pmid">10096380</pub-id></element-citation></ref><ref id="B59-vetsci-02-00456"><label>59.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Broder</surname><given-names>S.</given-names></name><name><surname>Yarchoan</surname><given-names>R.</given-names></name><name><surname>Collins</surname><given-names>J.M.</given-names></name><name><surname>Lane</surname><given-names>H.C.</given-names></name><name><surname>Markham</surname><given-names>P.D.</given-names></name><name><surname>Klecker</surname><given-names>R.W.</given-names></name><name><surname>Redfield</surname><given-names>R.R.</given-names></name><name><surname>Mitsuya</surname><given-names>H.</given-names></name><name><surname>Hoth</surname><given-names>D.F.</given-names></name><name><surname>Gelmann</surname><given-names>E.</given-names></name><etal/></person-group>
<article-title>Effects of suramin on HTLV-III/LAV infection presenting as Kaposi&#x02019;s Sarcoma or AIDS-related complex: Clinical pharmacology and suppression of virus replication <italic>in vivo</italic></article-title>
<source>Lancet</source>
<year>1985</year>
<volume>2</volume>
<fpage>627</fpage>
<lpage>630</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(85)90002-9</pub-id>
<pub-id pub-id-type="pmid">2863631</pub-id></element-citation></ref><ref id="B60-vetsci-02-00456"><label>60.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group>
<article-title>Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses</article-title>
<source>Cancer Lett.</source>
<year>1979</year>
<volume>8</volume>
<fpage>9</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1016/0304-3835(79)90017-X</pub-id>
<pub-id pub-id-type="pmid">92362</pub-id></element-citation></ref><ref id="B61-vetsci-02-00456"><label>61.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cogan</surname><given-names>D.C.</given-names></name><name><surname>Cotter</surname><given-names>S.M.</given-names></name><name><surname>Kitchen</surname><given-names>L.W.</given-names></name></person-group>
<article-title>Effect of suramin on serum viral replication in feline leukemia virus-infected pet cats</article-title>
<source>Am. J. Vet. Res.</source>
<year>1986</year>
<volume>47</volume>
<fpage>2230</fpage>
<lpage>2232</lpage>
<?supplied-pmid 3022623?><pub-id pub-id-type="pmid">3022623</pub-id></element-citation></ref><ref id="B62-vetsci-02-00456"><label>62.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abkowitz</surname><given-names>J.L.</given-names></name></person-group>
<article-title>Retrovirus-induced feline pure red blood cell aplasia: Pathogenesis and response to suramin</article-title>
<source>Blood</source>
<year>1991</year>
<volume>77</volume>
<fpage>1442</fpage>
<lpage>1451</lpage>
<?supplied-pmid 1849031?><pub-id pub-id-type="pmid">1849031</pub-id></element-citation></ref><ref id="B63-vetsci-02-00456"><label>63.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dorfinger</surname><given-names>K.</given-names></name><name><surname>Niederle</surname><given-names>B.</given-names></name><name><surname>Vierhapper</surname><given-names>H.</given-names></name><name><surname>Astrid</surname><given-names>W.</given-names></name><name><surname>Czernin</surname><given-names>S.</given-names></name><name><surname>Nowotny</surname><given-names>P.</given-names></name><name><surname>Waldhausl</surname><given-names>W.</given-names></name><name><surname>Grubeck-Loebenstein</surname><given-names>B.</given-names></name></person-group>
<article-title>Suramin and the human adrenocortex: Results of experimental and clinical studies</article-title>
<source>Surgery</source>
<year>1991</year>
<volume>110</volume>
<fpage>1100</fpage>
<lpage>1105</lpage>
<?supplied-pmid 1660627?><pub-id pub-id-type="pmid">1660627</pub-id></element-citation></ref><ref id="B64-vetsci-02-00456"><label>64.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaur</surname><given-names>M.</given-names></name><name><surname>Reed</surname><given-names>E.</given-names></name><name><surname>Sartor</surname><given-names>O.</given-names></name><name><surname>Dahut</surname><given-names>W.</given-names></name><name><surname>Figg</surname><given-names>W.D.</given-names></name></person-group>
<article-title>Suramin&#x02019;s development: What did we learn?</article-title>
<source>Investig. New Drugs</source>
<year>2002</year>
<volume>20</volume>
<fpage>209</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="doi">10.1023/A:1015666024386</pub-id>
<pub-id pub-id-type="pmid">12099581</pub-id></element-citation></ref><ref id="B65-vetsci-02-00456"><label>65.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>B.P.</given-names></name><name><surname>Dawson</surname><given-names>N.A.</given-names></name><name><surname>Weiss</surname><given-names>R.B.</given-names></name><name><surname>Myers</surname><given-names>C.E.</given-names></name><name><surname>James</surname><given-names>W.D.</given-names></name></person-group>
<article-title>Suramin-induced skin reactions</article-title>
<source>Arch. Dermatol.</source>
<year>1992</year>
<volume>128</volume>
<fpage>75</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.1001/archderm.1992.01680110085011</pub-id>
<?supplied-pmid 1531404?><pub-id pub-id-type="pmid">1531404</pub-id></element-citation></ref><ref id="B66-vetsci-02-00456"><label>66.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Crumpacker</surname><given-names>C.S.</given-names></name></person-group>
<article-title>Mechanism of action of foscarnet against viral polymerases</article-title>
<source>Am. J. Med.</source>
<year>1992</year>
<volume>92</volume>
<fpage>3S</fpage>
<lpage>7S</lpage>
<pub-id pub-id-type="doi">10.1016/0002-9343(92)90329-A</pub-id>
</element-citation></ref><ref id="B67-vetsci-02-00456"><label>67.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Smith</surname><given-names>K.P.</given-names></name></person-group>
<article-title>Safety of alternative antiviral agents for neonatal herpes simplex virus encephalitis and disseminated infection</article-title>
<source>J. Pediatr. Pharmacol. Ther.</source>
<year>2014</year>
<volume>19</volume>
<fpage>72</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.5863/1551-6776-19.2.72</pub-id>
<?supplied-pmid 25024666?><pub-id pub-id-type="pmid">25024666</pub-id></element-citation></ref><ref id="B68-vetsci-02-00456"><label>68.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Straw</surname><given-names>J.A.</given-names></name><name><surname>Loo</surname><given-names>T.L.</given-names></name><name><surname>de Vera</surname><given-names>C.C.</given-names></name><name><surname>Nelson</surname><given-names>P.D.</given-names></name><name><surname>Tompkins</surname><given-names>W.A.</given-names></name><name><surname>Bai</surname><given-names>S.A.</given-names></name></person-group>
<article-title>Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat</article-title>
<source>J. Acquir. Immun. Defic. Syndr.</source>
<year>1992</year>
<volume>5</volume>
<fpage>936</fpage>
<lpage>942</lpage>
</element-citation></ref><ref id="B69-vetsci-02-00456"><label>69.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gerard</surname><given-names>L.</given-names></name><name><surname>Salmon-Ceron</surname><given-names>D.</given-names></name></person-group>
<article-title>Pharmacology and clinical use of foscarnet</article-title>
<source>Int. J. Antimicrob. Agents</source>
<year>1995</year>
<volume>5</volume>
<fpage>209</fpage>
<lpage>217</lpage>
<pub-id pub-id-type="doi">10.1016/0924-8579(95)00008-V</pub-id>
<pub-id pub-id-type="pmid">18611671</pub-id></element-citation></ref><ref id="B70-vetsci-02-00456"><label>70.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ryrfeldt</surname><given-names>A.</given-names></name><name><surname>Nordgren</surname><given-names>T.</given-names></name><name><surname>Lundstrom</surname><given-names>J.</given-names></name></person-group>
<article-title>Hypocalcemia induced by foscarnet (Foscavir) infusion in dogs</article-title>
<source>Fundam. Appl. Toxicol.</source>
<year>1992</year>
<volume>18</volume>
<fpage>126</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1016/0272-0590(92)90204-U</pub-id>
<pub-id pub-id-type="pmid">1534776</pub-id></element-citation></ref><ref id="B71-vetsci-02-00456"><label>71.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beaucourt</surname><given-names>S.</given-names></name><name><surname>Vignuzzi</surname><given-names>M.</given-names></name></person-group>
<article-title>Ribavirin: A drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance</article-title>
<source>Curr. Opin. Virol.</source>
<year>2014</year>
<volume>8</volume>
<fpage>10</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1016/j.coviro.2014.04.011</pub-id>
<?supplied-pmid 24846716?><pub-id pub-id-type="pmid">24846716</pub-id></element-citation></ref><ref id="B72-vetsci-02-00456"><label>72.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lafeuillade</surname><given-names>A.</given-names></name><name><surname>Hittinger</surname><given-names>G.</given-names></name><name><surname>Chadapaud</surname><given-names>S.</given-names></name></person-group>
<article-title>Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection</article-title>
<source>Lancet</source>
<year>2001</year>
<volume>357</volume>
<fpage>280</fpage>
<lpage>281</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(00)03618-7</pub-id>
<pub-id pub-id-type="pmid">11214134</pub-id></element-citation></ref><ref id="B73-vetsci-02-00456"><label>73.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Povey</surname><given-names>R.C.</given-names></name></person-group>
<article-title>Effect of orally administered ribavirin on experimental feline calicivirus infection in cats</article-title>
<source>Am. J. Vet. Res.</source>
<year>1978</year>
<volume>39</volume>
<fpage>1337</fpage>
<lpage>1341</lpage>
<?supplied-pmid 697143?><pub-id pub-id-type="pmid">697143</pub-id></element-citation></ref><ref id="B74-vetsci-02-00456"><label>74.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weiss</surname><given-names>R.C.</given-names></name><name><surname>Cox</surname><given-names>N.R.</given-names></name><name><surname>Boudreaux</surname><given-names>M.K.</given-names></name></person-group>
<article-title>Toxicologic effects of ribavirin in cats</article-title>
<source>J. Vet. Pharmacol. Ther.</source>
<year>1993</year>
<volume>16</volume>
<fpage>301</fpage>
<lpage>316</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2885.1993.tb00177.x</pub-id>
<?supplied-pmid 8230401?><pub-id pub-id-type="pmid">8230401</pub-id></element-citation></ref><ref id="B75-vetsci-02-00456"><label>75.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weiss</surname><given-names>R.C.</given-names></name><name><surname>Cox</surname><given-names>N.R.</given-names></name><name><surname>Martinez</surname><given-names>M.L.</given-names></name></person-group>
<article-title>Evaluation of free or liposome-encapsulated ribavirin for antiviral therapy of experimentally induced feline infectious peritonitis</article-title>
<source>Res. Vet. Sci.</source>
<year>1993</year>
<volume>55</volume>
<fpage>162</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="doi">10.1016/0034-5288(93)90076-R</pub-id>
<pub-id pub-id-type="pmid">8235082</pub-id></element-citation></ref><ref id="B76-vetsci-02-00456"><label>76.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Greene</surname><given-names>C.E.</given-names></name><name><surname>Watson</surname><given-names>A.D.J.</given-names></name></person-group>
<article-title>Antiviral drugs</article-title>
<source>Infectious Diseases of the Dog and Cat</source>
<edition>2nd ed.</edition>
<person-group person-group-type="editor"><name><surname>Greene</surname><given-names>C.E.</given-names></name></person-group>
<publisher-name>Elsevier Saunders</publisher-name>
<publisher-loc>St. Louis, MO, USA</publisher-loc>
<year>1998</year>
<fpage>6</fpage>
<lpage>9</lpage>
</element-citation></ref><ref id="B77-vetsci-02-00456"><label>77.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rucker</surname><given-names>J.</given-names></name><name><surname>Edinger</surname><given-names>A.L.</given-names></name><name><surname>Sharron</surname><given-names>M.</given-names></name><name><surname>Samson</surname><given-names>M.</given-names></name><name><surname>Lee</surname><given-names>B.</given-names></name><name><surname>Berson</surname><given-names>J.F.</given-names></name><name><surname>Yi</surname><given-names>Y.</given-names></name><name><surname>Margulies</surname><given-names>B.</given-names></name><name><surname>Collman</surname><given-names>R.G.</given-names></name><name><surname>Doranz</surname><given-names>B.J.</given-names></name><etal/></person-group>
<article-title>Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses</article-title>
<source>J. Virol.</source>
<year>1997</year>
<volume>71</volume>
<fpage>8999</fpage>
<lpage>9007</lpage>
<?supplied-pmid 9371556?><pub-id pub-id-type="pmid">9371556</pub-id></element-citation></ref><ref id="B78-vetsci-02-00456"><label>78.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Willett</surname><given-names>B.J.</given-names></name><name><surname>Hosie</surname><given-names>M.J.</given-names></name></person-group>
<article-title>The role of the chemokine receptor CXCR4 in infection with feline immunodeficiency virus</article-title>
<source>Mol. Membr. Biol.</source>
<year>1999</year>
<volume>16</volume>
<fpage>67</fpage>
<lpage>72</lpage>
<?supplied-pmid 10332739?><pub-id pub-id-type="pmid">10332739</pub-id></element-citation></ref><ref id="B79-vetsci-02-00456"><label>79.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Willett</surname><given-names>B.J.</given-names></name><name><surname>Picard</surname><given-names>L.</given-names></name><name><surname>Hosie</surname><given-names>M.J.</given-names></name><name><surname>Turner</surname><given-names>J.D.</given-names></name><name><surname>Adema</surname><given-names>K.</given-names></name><name><surname>Clapham</surname><given-names>P.R.</given-names></name></person-group>
<article-title>Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses</article-title>
<source>J. Virol.</source>
<year>1997</year>
<volume>71</volume>
<fpage>6407</fpage>
<lpage>6415</lpage>
<?supplied-pmid 9261358?><pub-id pub-id-type="pmid">9261358</pub-id></element-citation></ref><ref id="B80-vetsci-02-00456"><label>80.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wells</surname><given-names>T.N.</given-names></name><name><surname>Proudfoot</surname><given-names>A.E.</given-names></name><name><surname>Power</surname><given-names>C.A.</given-names></name><name><surname>Marsh</surname><given-names>M.</given-names></name></person-group>
<article-title>Chemokine receptors&#x02014;The new frontier for AIDS research</article-title>
<source>Chem. Biol.</source>
<year>1996</year>
<volume>3</volume>
<fpage>603</fpage>
<lpage>609</lpage>
<pub-id pub-id-type="doi">10.1016/S1074-5521(96)90126-X</pub-id>
<pub-id pub-id-type="pmid">8807892</pub-id></element-citation></ref><ref id="B81-vetsci-02-00456"><label>81.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Donzella</surname><given-names>G.A.</given-names></name><name><surname>Schols</surname><given-names>D.</given-names></name><name><surname>Lin</surname><given-names>S.W.</given-names></name><name><surname>Este</surname><given-names>J.A.</given-names></name><name><surname>Nagashima</surname><given-names>K.A.</given-names></name><name><surname>Maddon</surname><given-names>P.J.</given-names></name><name><surname>Allaway</surname><given-names>G.P.</given-names></name><name><surname>Sakmar</surname><given-names>T.P.</given-names></name><name><surname>Henson</surname><given-names>G.</given-names></name><name><surname>de Clercq</surname><given-names>E.</given-names></name><etal/></person-group>
<article-title>AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor</article-title>
<source>Nat. Med.</source>
<year>1998</year>
<volume>4</volume>
<fpage>72</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1038/nm0198-072</pub-id>
<?supplied-pmid 9427609?><pub-id pub-id-type="pmid">9427609</pub-id></element-citation></ref><ref id="B82-vetsci-02-00456"><label>82.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Egberink</surname><given-names>H.F.</given-names></name><name><surname>de Clercq</surname><given-names>E.</given-names></name><name><surname>van Vliet</surname><given-names>A.L.</given-names></name><name><surname>Balzarini</surname><given-names>J.</given-names></name><name><surname>Bridger</surname><given-names>G.J.</given-names></name><name><surname>Henson</surname><given-names>G.</given-names></name><name><surname>Horzinek</surname><given-names>M.C.</given-names></name><name><surname>Schols</surname><given-names>D.</given-names></name></person-group>
<article-title>Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication</article-title>
<source>J. Virol.</source>
<year>1999</year>
<volume>73</volume>
<fpage>6346</fpage>
<lpage>6352</lpage>
<?supplied-pmid 10400726?><pub-id pub-id-type="pmid">10400726</pub-id></element-citation></ref><ref id="B83-vetsci-02-00456"><label>83.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schols</surname><given-names>D.</given-names></name><name><surname>Este</surname><given-names>J.A.</given-names></name><name><surname>Henson</surname><given-names>G.</given-names></name><name><surname>de Clercq</surname><given-names>E.</given-names></name></person-group>
<article-title>Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor Fusin/CXCR-4</article-title>
<source>Antivir. Res.</source>
<year>1997</year>
<volume>35</volume>
<fpage>147</fpage>
<lpage>156</lpage>
<pub-id pub-id-type="doi">10.1016/S0166-3542(97)00025-9</pub-id>
<pub-id pub-id-type="pmid">9298754</pub-id></element-citation></ref><ref id="B84-vetsci-02-00456"><label>84.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liles</surname><given-names>W.C.</given-names></name><name><surname>Broxmeyer</surname><given-names>H.E.</given-names></name><name><surname>Rodger</surname><given-names>E.</given-names></name><name><surname>Wood</surname><given-names>B.</given-names></name><name><surname>Hubel</surname><given-names>K.</given-names></name><name><surname>Cooper</surname><given-names>S.</given-names></name><name><surname>Hangoc</surname><given-names>G.</given-names></name><name><surname>Bridger</surname><given-names>G.J.</given-names></name><name><surname>Henson</surname><given-names>G.W.</given-names></name><name><surname>Calandra</surname><given-names>G.</given-names></name><etal/></person-group>
<article-title>Mobilization of hematopoietic progenitor cells in healthy volunteers by amd3100, a CXCR4 antagonist</article-title>
<source>Blood</source>
<year>2003</year>
<volume>102</volume>
<fpage>2728</fpage>
<lpage>2730</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2003-02-0663</pub-id>
<?supplied-pmid 12855591?><pub-id pub-id-type="pmid">12855591</pub-id></element-citation></ref><ref id="B85-vetsci-02-00456"><label>85.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Norelli</surname><given-names>S.</given-names></name><name><surname>El Daker</surname><given-names>S.</given-names></name><name><surname>D&#x02019;Ostilio</surname><given-names>D.</given-names></name><name><surname>Mele</surname><given-names>F.</given-names></name><name><surname>Mancini</surname><given-names>F.</given-names></name><name><surname>Taglia</surname><given-names>F.</given-names></name><name><surname>Ruggieri</surname><given-names>A.</given-names></name><name><surname>Ciccozzi</surname><given-names>M.</given-names></name><name><surname>Cauda</surname><given-names>R.</given-names></name><name><surname>Ciervo</surname><given-names>A.</given-names></name><etal/></person-group>
<article-title>Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistent HIV-1</article-title>
<source>Curr. HIV Res.</source>
<year>2008</year>
<volume>6</volume>
<fpage>306</fpage>
<lpage>317</lpage>
<pub-id pub-id-type="doi">10.2174/157016208785132527</pub-id>
<?supplied-pmid 18691029?><pub-id pub-id-type="pmid">18691029</pub-id></element-citation></ref><ref id="B86-vetsci-02-00456"><label>86.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>T.</given-names></name><name><surname>Laco</surname><given-names>G.S.</given-names></name><name><surname>Torbett</surname><given-names>B.E.</given-names></name><name><surname>Fox</surname><given-names>H.S.</given-names></name><name><surname>Lerner</surname><given-names>D.L.</given-names></name><name><surname>Elder</surname><given-names>J.H.</given-names></name><name><surname>Wong</surname><given-names>C.H.</given-names></name></person-group>
<article-title>Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV <italic>in vitro</italic> and <italic>ex vivo</italic></article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>1998</year>
<volume>95</volume>
<fpage>939</fpage>
<lpage>944</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.95.3.939</pub-id>
<?supplied-pmid 9448264?><pub-id pub-id-type="pmid">9448264</pub-id></element-citation></ref><ref id="B87-vetsci-02-00456"><label>87.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huitron-Resendiz</surname><given-names>S.</given-names></name><name><surname>de Rozi&#x000e8;res</surname><given-names>S.</given-names></name><name><surname>Sanchez-Alavez</surname><given-names>M.</given-names></name><name><surname>B&#x000fc;hler</surname><given-names>B.</given-names></name><name><surname>Lin</surname><given-names>Y.C.</given-names></name><name><surname>Lerner</surname><given-names>D.L.</given-names></name><name><surname>Henriksen</surname><given-names>N.W.</given-names></name><name><surname>Burudi</surname><given-names>M.</given-names></name><name><surname>Fox</surname><given-names>H.S.</given-names></name><name><surname>Torbett</surname><given-names>B.E.</given-names></name><etal/></person-group>
<article-title>Resolution and prevention of feline immunodeficiency virus-induced neurological deficits by treatment with the protease inhibitor TL-3</article-title>
<source>J. Virol.</source>
<year>2004</year>
<volume>78</volume>
<fpage>4525</fpage>
<lpage>4532</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.78.9.4525-4532.2004</pub-id>
<?supplied-pmid 15078933?><pub-id pub-id-type="pmid">15078933</pub-id></element-citation></ref><ref id="B88-vetsci-02-00456"><label>88.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zeinalipour-Loizidou</surname><given-names>E.</given-names></name><name><surname>Nicolaou</surname><given-names>C.</given-names></name><name><surname>Nicolaides</surname><given-names>A.</given-names></name><name><surname>Kostrikis</surname><given-names>L.G.</given-names></name></person-group>
<article-title>HIV-1 integrase: From biology to chemotherapeutics</article-title>
<source>Curr. HIV Res.</source>
<year>2007</year>
<volume>5</volume>
<fpage>365</fpage>
<lpage>388</lpage>
<pub-id pub-id-type="doi">10.2174/157016207781023965</pub-id>
<?supplied-pmid 17627500?><pub-id pub-id-type="pmid">17627500</pub-id></element-citation></ref><ref id="B89-vetsci-02-00456"><label>89.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mouscadet</surname><given-names>J.F.</given-names></name><name><surname>Arora</surname><given-names>R.</given-names></name><name><surname>Andre</surname><given-names>J.</given-names></name><name><surname>Lambry</surname><given-names>J.C.</given-names></name><name><surname>Delelis</surname><given-names>O.</given-names></name><name><surname>Malet</surname><given-names>I.</given-names></name><name><surname>Marcelin</surname><given-names>A.G.</given-names></name><name><surname>Calvez</surname><given-names>V.</given-names></name><name><surname>Tchertanov</surname><given-names>L.</given-names></name></person-group>
<article-title>HIV-1 in alternative molecular recognition of DNA induced by raltegravir resistance mutations</article-title>
<source>J. Mol. Recognit.</source>
<year>2009</year>
<volume>22</volume>
<fpage>480</fpage>
<lpage>494</lpage>
<pub-id pub-id-type="doi">10.1002/jmr.970</pub-id>
<?supplied-pmid 19623602?><pub-id pub-id-type="pmid">19623602</pub-id></element-citation></ref><ref id="B90-vetsci-02-00456"><label>90.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cattori</surname><given-names>V.</given-names></name><name><surname>Weibel</surname><given-names>B.</given-names></name><name><surname>Lutz</surname><given-names>H.</given-names></name></person-group>
<article-title>Inhibition of feline leukemia virus replication by the integrase inhibitor raltegravir</article-title>
<source>Vet. Microbiol.</source>
<year>2011</year>
<volume>152</volume>
<fpage>165</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="doi">10.1016/j.vetmic.2011.03.039</pub-id>
<?supplied-pmid 21570781?><pub-id pub-id-type="pmid">21570781</pub-id></element-citation></ref><ref id="B91-vetsci-02-00456"><label>91.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Greggs</surname><given-names>W.M.</given-names><suffix>3rd</suffix></name><name><surname>Clouser</surname><given-names>C.L.</given-names></name><name><surname>Patterson</surname><given-names>S.E.</given-names></name><name><surname>Mansky</surname><given-names>L.M.</given-names></name></person-group>
<article-title>Discovery of drugs that possess activity against feline leukemia virus</article-title>
<source>J. Gen. Virol.</source>
<year>2012</year>
<volume>93</volume>
<fpage>900</fpage>
<lpage>905</lpage>
<pub-id pub-id-type="doi">10.1099/vir.0.039909-0</pub-id>
<?supplied-pmid 22258856?><pub-id pub-id-type="pmid">22258856</pub-id></element-citation></ref><ref id="B92-vetsci-02-00456"><label>92.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Togami</surname><given-names>H.</given-names></name><name><surname>Shimura</surname><given-names>K.</given-names></name><name><surname>Okamoto</surname><given-names>M.</given-names></name><name><surname>Yoshikawa</surname><given-names>R.</given-names></name><name><surname>Miyazawa</surname><given-names>T.</given-names></name><name><surname>Matsuoka</surname><given-names>M.</given-names></name></person-group>
<article-title>Comprehensive <italic>in vitro</italic> analysis of simian retrovirus type 4 susceptibility to antiretroviral agents</article-title>
<source>J. Virol.</source>
<year>2013</year>
<volume>87</volume>
<fpage>4322</fpage>
<lpage>4329</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.03208-12</pub-id>
<?supplied-pmid 23365453?><pub-id pub-id-type="pmid">23365453</pub-id></element-citation></ref><ref id="B93-vetsci-02-00456"><label>93.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boesch</surname><given-names>A.</given-names></name><name><surname>Cattori</surname><given-names>V.</given-names></name><name><surname>Riond</surname><given-names>B.</given-names></name><name><surname>Willi</surname><given-names>B.</given-names></name><name><surname>Meli</surname><given-names>M.L.</given-names></name><name><surname>Rentsch</surname><given-names>K.M.</given-names></name><name><surname>Hosie</surname><given-names>M.J.</given-names></name><name><surname>Hofmann-Lehmann</surname><given-names>R.</given-names></name><name><surname>Lutz</surname><given-names>H.</given-names></name></person-group>
<article-title>Evaluation of the effect of short-term treatment with the integrase inhibitor raltegravir (Isentress) on the course of progressive feline leukemia virus infection</article-title>
<source>Vet. Microbial.</source>
<year>2015</year>
<volume>175</volume>
<fpage>167</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="doi">10.1016/j.vetmic.2014.10.031</pub-id>
<?supplied-pmid 25500005?><pub-id pub-id-type="pmid">25500005</pub-id></element-citation></ref><ref id="B94-vetsci-02-00456"><label>94.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Domenech</surname><given-names>A.</given-names></name><name><surname>Miro</surname><given-names>G.</given-names></name><name><surname>Collado</surname><given-names>V.M.</given-names></name><name><surname>Ballesteros</surname><given-names>N.</given-names></name><name><surname>Sanjose</surname><given-names>L.</given-names></name><name><surname>Escolar</surname><given-names>E.</given-names></name><name><surname>Martin</surname><given-names>S.</given-names></name><name><surname>Gomez-Lucia</surname><given-names>E.</given-names></name></person-group>
<article-title>Use of recombinant interferon omega in feline retrovirosis: From theory to practice</article-title>
<source>Vet. Immunol. Immunopathol.</source>
<year>2011</year>
<volume>143</volume>
<fpage>301</fpage>
<lpage>306</lpage>
<pub-id pub-id-type="doi">10.1016/j.vetimm.2011.06.008</pub-id>
<?supplied-pmid 21719116?><pub-id pub-id-type="pmid">21719116</pub-id></element-citation></ref><ref id="B95-vetsci-02-00456"><label>95.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stark</surname><given-names>J.J.</given-names></name><name><surname>Dillman</surname><given-names>R.O.</given-names></name><name><surname>Schulof</surname><given-names>R.</given-names></name><name><surname>Wiemann</surname><given-names>M.C.</given-names></name><name><surname>Barth</surname><given-names>N.M.</given-names></name><name><surname>Honeycutt</surname><given-names>P.J.</given-names></name><name><surname>Soori</surname><given-names>G.</given-names></name></person-group>
<article-title>Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: Final results of a phase I&#x02013;II study of the cancer biotherapy research group and the mid-atlantic oncology program</article-title>
<source>Cancer</source>
<year>1998</year>
<volume>82</volume>
<fpage>1677</fpage>
<lpage>1681</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19980501)82:9&#x0003c;1677::AID-CNCR13&#x0003e;3.0.CO;2-1</pub-id>
<pub-id pub-id-type="pmid">9576288</pub-id></element-citation></ref><ref id="B96-vetsci-02-00456"><label>96.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gil</surname><given-names>S.</given-names></name><name><surname>Leal</surname><given-names>R.O.</given-names></name><name><surname>Duarte</surname><given-names>A.</given-names></name><name><surname>McGahie</surname><given-names>D.</given-names></name><name><surname>Sepulveda</surname><given-names>N.</given-names></name><name><surname>Siborro</surname><given-names>I.</given-names></name><name><surname>Cravo</surname><given-names>J.</given-names></name><name><surname>Cartaxeiro</surname><given-names>C.</given-names></name><name><surname>Tavares</surname><given-names>L.M.</given-names></name></person-group>
<article-title>Relevance of feline interferon omega for clinical improvement and reduction of concurrent viral excretion in retrovirus infected cats from a rescue shelter</article-title>
<source>Res. Vet. Sci.</source>
<year>2013</year>
<volume>94</volume>
<fpage>753</fpage>
<lpage>763</lpage>
<pub-id pub-id-type="doi">10.1016/j.rvsc.2012.09.025</pub-id>
<?supplied-pmid 23122808?><pub-id pub-id-type="pmid">23122808</pub-id></element-citation></ref><ref id="B97-vetsci-02-00456"><label>97.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goodbourn</surname><given-names>S.</given-names></name><name><surname>Didcock</surname><given-names>L.</given-names></name><name><surname>Randall</surname><given-names>R.E.</given-names></name></person-group>
<article-title>Interferons: Cell signalling, immune modulation, antiviral response and virus countermeasures</article-title>
<source>J. Gen. Virol.</source>
<year>2000</year>
<volume>81</volume>
<fpage>2341</fpage>
<lpage>2364</lpage>
<pub-id pub-id-type="doi">10.1099/0022-1317-81-10-2341</pub-id>
<?supplied-pmid 10993923?><pub-id pub-id-type="pmid">10993923</pub-id></element-citation></ref><ref id="B98-vetsci-02-00456"><label>98.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gerlach</surname><given-names>N.</given-names></name><name><surname>Gibbert</surname><given-names>K.</given-names></name><name><surname>Alter</surname><given-names>C.</given-names></name><name><surname>Nair</surname><given-names>S.</given-names></name><name><surname>Zelinskyy</surname><given-names>G.</given-names></name><name><surname>James</surname><given-names>C.M.</given-names></name><name><surname>Dittmer</surname><given-names>U.</given-names></name></person-group>
<article-title>Anti-retroviral effects of type I IFN subtypes <italic>in vivo</italic></article-title>
<source>Eur. J. Immunol.</source>
<year>2009</year>
<volume>39</volume>
<fpage>136</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="doi">10.1002/eji.200838311</pub-id>
<?supplied-pmid 19130550?><pub-id pub-id-type="pmid">19130550</pub-id></element-citation></ref><ref id="B99-vetsci-02-00456"><label>99.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gomez-Lucia</surname><given-names>E.</given-names></name><name><surname>Collado</surname><given-names>V.M.</given-names></name><name><surname>Miro</surname><given-names>G.</given-names></name><name><surname>Domenech</surname><given-names>A.</given-names></name></person-group>
<article-title>Effect of type-I interferon on retroviruses</article-title>
<source>Viruses</source>
<year>2009</year>
<volume>1</volume>
<fpage>545</fpage>
<lpage>573</lpage>
<pub-id pub-id-type="doi">10.3390/v1030545</pub-id>
<?supplied-pmid 21994560?><pub-id pub-id-type="pmid">21994560</pub-id></element-citation></ref><ref id="B100-vetsci-02-00456"><label>100.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zeidner</surname><given-names>N.S.</given-names></name><name><surname>Myles</surname><given-names>M.H.</given-names></name><name><surname>Mathiason-DuBard</surname><given-names>C.K.</given-names></name><name><surname>Dreitz</surname><given-names>M.J.</given-names></name><name><surname>Mullins</surname><given-names>J.I.</given-names></name><name><surname>Hoover</surname><given-names>E.A.</given-names></name></person-group>
<article-title>Alpha interferon (2&#x003b2;) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>1990</year>
<volume>34</volume>
<fpage>1749</fpage>
<lpage>1756</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.34.9.1749</pub-id>
<?supplied-pmid 2178336?><pub-id pub-id-type="pmid">2178336</pub-id></element-citation></ref><ref id="B101-vetsci-02-00456"><label>101.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cantell</surname><given-names>K.</given-names></name><name><surname>Pyhala</surname><given-names>L.</given-names></name></person-group>
<article-title>Circulating interferon in rabbits after administration of human interferon by different routes</article-title>
<source>J. Gen. Virol.</source>
<year>1973</year>
<volume>20</volume>
<fpage>97</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="doi">10.1099/0022-1317-20-1-97</pub-id>
<?supplied-pmid 4356685?><pub-id pub-id-type="pmid">4356685</pub-id></element-citation></ref><ref id="B102-vetsci-02-00456"><label>102.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cummins</surname><given-names>J.M.</given-names></name><name><surname>Beilharz</surname><given-names>M.W.</given-names></name><name><surname>Krakowka</surname><given-names>S.</given-names></name></person-group>
<article-title>Oral use of interferon</article-title>
<source>J. Interferon Cytokine Res.</source>
<year>1999</year>
<volume>19</volume>
<fpage>853</fpage>
<lpage>857</lpage>
<pub-id pub-id-type="doi">10.1089/107999099313352</pub-id>
<?supplied-pmid 10476928?><pub-id pub-id-type="pmid">10476928</pub-id></element-citation></ref><ref id="B103-vetsci-02-00456"><label>103.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koech</surname><given-names>D.K.</given-names></name><name><surname>Obel</surname><given-names>A.O.</given-names></name></person-group>
<article-title>Efficacy of kemron (low dose oral natural human interferon alpha) in the management of HIV-1 infection and acquired immune deficiency syndrome (AIDS)</article-title>
<source>East. Afr. Med. J.</source>
<year>1990</year>
<volume>67</volume>
<fpage>64</fpage>
<lpage>70</lpage>
</element-citation></ref><ref id="B104-vetsci-02-00456"><label>104.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tompkins</surname><given-names>W.A.</given-names></name></person-group>
<article-title>Immunomodulation and therapeutic effects of the oral use of interferon-alpha: Mechanism of action</article-title>
<source>J. Interferon Cytokine Res.</source>
<year>1999</year>
<volume>19</volume>
<fpage>817</fpage>
<lpage>828</lpage>
<pub-id pub-id-type="doi">10.1089/107999099313325</pub-id>
<?supplied-pmid 10476925?><pub-id pub-id-type="pmid">10476925</pub-id></element-citation></ref><ref id="B105-vetsci-02-00456"><label>105.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tanabe</surname><given-names>T.</given-names></name><name><surname>Yamamoto</surname><given-names>J.K.</given-names></name></person-group>
<article-title>Feline immunodeficiency virus lacks sensitivity to the antiviral activity of feline ifn-gamma</article-title>
<source>J. Interferon Cytokine Res.</source>
<year>2001</year>
<volume>21</volume>
<fpage>1039</fpage>
<lpage>1046</lpage>
<pub-id pub-id-type="doi">10.1089/107999001317205169</pub-id>
<?supplied-pmid 11798461?><pub-id pub-id-type="pmid">11798461</pub-id></element-citation></ref><ref id="B106-vetsci-02-00456"><label>106.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pedretti</surname><given-names>E.</given-names></name><name><surname>Passeri</surname><given-names>B.</given-names></name><name><surname>Amadori</surname><given-names>M.</given-names></name><name><surname>Isola</surname><given-names>P.</given-names></name><name><surname>di Pede</surname><given-names>P.</given-names></name><name><surname>Telera</surname><given-names>A.</given-names></name><name><surname>Vescovini</surname><given-names>R.</given-names></name><name><surname>Quintavalla</surname><given-names>F.</given-names></name><name><surname>Pistello</surname><given-names>M.</given-names></name></person-group>
<article-title>Low-dose interferon-alpha treatment for feline immunodeficiency virus infection</article-title>
<source>Vet. Immunol. Immunopathol.</source>
<year>2006</year>
<volume>109</volume>
<fpage>245</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.1016/j.vetimm.2005.08.020</pub-id>
<?supplied-pmid 16169599?><pub-id pub-id-type="pmid">16169599</pub-id></element-citation></ref><ref id="B107-vetsci-02-00456"><label>107.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Mari</surname><given-names>K.</given-names></name><name><surname>Maynard</surname><given-names>L.</given-names></name><name><surname>Sanquer</surname><given-names>A.</given-names></name><name><surname>Lebreux</surname><given-names>B.</given-names></name><name><surname>Eun</surname><given-names>H.M.</given-names></name></person-group>
<article-title>Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FELV)-infected and FELV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats</article-title>
<source>J. Vet. Intern. Med./Am. Coll. Vet. Intern. Med.</source>
<year>2004</year>
<volume>18</volume>
<fpage>477</fpage>
<lpage>482</lpage>
<pub-id pub-id-type="doi">10.1892/0891-6640(2004)18&#x0003c;477:TEORFI&#x0003e;2.0.CO;2</pub-id>
</element-citation></ref><ref id="B108-vetsci-02-00456"><label>108.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gil</surname><given-names>S.</given-names></name><name><surname>Leal</surname><given-names>R.O.</given-names></name><name><surname>McGahie</surname><given-names>D.</given-names></name><name><surname>Sepulveda</surname><given-names>N.</given-names></name><name><surname>Duarte</surname><given-names>A.</given-names></name><name><surname>Niza</surname><given-names>M.M.</given-names></name><name><surname>Tavares</surname><given-names>L.</given-names></name></person-group>
<article-title>Oral recombinant feline interferon-omega as an alternative immune modulation therapy in FIV positive cats: Clinical and laboratory evaluation</article-title>
<source>Res. Vet. Sci.</source>
<year>2014</year>
<volume>96</volume>
<fpage>79</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1016/j.rvsc.2013.11.007</pub-id>
<?supplied-pmid 24332273?><pub-id pub-id-type="pmid">24332273</pub-id></element-citation></ref><ref id="B109-vetsci-02-00456"><label>109.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leal</surname><given-names>R.O.</given-names></name><name><surname>Gil</surname><given-names>S.</given-names></name><name><surname>Duarte</surname><given-names>A.</given-names></name><name><surname>McGahie</surname><given-names>D.</given-names></name><name><surname>Sepulveda</surname><given-names>N.</given-names></name><name><surname>Niza</surname><given-names>M.M.</given-names></name><name><surname>Tavares</surname><given-names>L.</given-names></name></person-group>
<article-title>Evaluation of viremia, proviral load and cytokine profile in naturally feline immunodeficiency virus infected cats treated with two different protocols of recombinant feline interferon omega</article-title>
<source>Res. Vet. Sci.</source>
<year>2015</year>
<volume>99</volume>
<fpage>87</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="doi">10.1016/j.rvsc.2015.02.008</pub-id>
<?supplied-pmid 25747956?><pub-id pub-id-type="pmid">25747956</pub-id></element-citation></ref><ref id="B110-vetsci-02-00456"><label>110.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hosie</surname><given-names>M.J.</given-names></name><name><surname>Addie</surname><given-names>D.</given-names></name><name><surname>Belak</surname><given-names>S.</given-names></name><name><surname>Boucraut-Baralon</surname><given-names>C.</given-names></name><name><surname>Egberink</surname><given-names>H.</given-names></name><name><surname>Frymus</surname><given-names>T.</given-names></name><name><surname>Gruffydd-Jones</surname><given-names>T.</given-names></name><name><surname>Hartmann</surname><given-names>K.</given-names></name><name><surname>Lloret</surname><given-names>A.</given-names></name><name><surname>Lutz</surname><given-names>H.</given-names></name><etal/></person-group>
<article-title>Feline immunodeficiency. ABCD guidelines on prevention and management</article-title>
<source>J. Feline Med. Surg.</source>
<year>2009</year>
<volume>11</volume>
<fpage>575</fpage>
<lpage>584</lpage>
<pub-id pub-id-type="doi">10.1016/j.jfms.2009.05.006</pub-id>
<?supplied-pmid 19481037?><pub-id pub-id-type="pmid">19481037</pub-id></element-citation></ref></ref-list></back></article>